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1.1 Structural biology 
 
“Unfortunately, we cannot accurately describe at the chemical level how a molecule 
functions unless we first know its structure”. These few words, pronounced in 1964 
by James Watson, summarize in a very immediate and simple way the relevance 
that structural biology hold among all the scientific fields. This discipline focuses 
on providing a unique insight about the architecture, the dynamics and the 
interactions of biological macromolecules, such as proteins and nucleic acids. 
Thanks to the combination of biophysical, biochemical and molecular biology 
techniques it is possible to unveil, at atomic resolution, the three-dimensional 
structure of biomolecules and obtain fundamental mechanistic information about 
the biological processes in which they are involved. In particular we can reconstruct 
the dynamic complexity of cellular machinery, which often relies on intricate 
networks of competing interactions that form and dissolve in a time-depended way. 
The structure of enzymes and other categories of proteins is strictly connected to 
their functions and it is crucial for the correct interaction with other molecular 
partners. Furthermore, to highlight the importance of the structure, it is well known 
that many pathological states are caused by protein misfolding and, often, in viral 
or bacterial infections, the pathogen adhesion process to the host cell is driven by 
the recognition of precise structural motifs on the cell membrane. In this regard, it 
is recognized that understanding the exact structures of proteins can accelerate the 
progress of the drug discovery pipeline, by providing a detailed source of 
information such as target shape, macromolecules hydrophobic or hydrophilic 
behaviors and substrate interactions (Blundell, Jhoti, and Abell 2002). The 
aforementioned collected data can be extremely useful in designing ligands with 
complementary binding properties thus to optimize their potency and specificity 
(Bassetto et al. 2016). Various techniques with multiple features can be exploited 
for structurally characterizing macromolecules. They are Nuclear Magnetic 
Resonance (NMR), X-ray crystallography and cryo-Electron Microscopy (cryo-
EM), regarding the high-resolution techniques, and Small Angle X-ray Scattering 
(SAXS), Electron Paramagnetic Resonance (EPR), Circular Dichroism (CD), 
Fluorescence Resonance Energy Transfer (FRET), just to name a few, regarding 
the low-resolution techniques. However, to adequately investigate and describe in 
detail all the aspects of a biological system, the application of a single methodology 
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is often not sufficient. In fact, individual structural data results incomplete in 
purpose and accuracy due to the intrinsic limitations of each technique. For this 
reason, more complete structural information can be achieved only through the use 
of an integrated approach combining together two or more methodologies. In the 
last years, the interest on the correlation between structure of macromolecules and 
functional processes they are involved in has grown considerably. As a 
consequence, obtaining structural information at atomic resolution directly in a 
cellular context can be crucial to connect structural biology data with that obtained 
from other disciplines as cell biology and biochemistry. To do that NMR has proven 
to be the most suitable technique (Luchinat and Banci 2018). 
 
1.2 In vitro and in-cell NMR 
 
Nuclear magnetic resonance spectroscopy has established as one of the most 
powerful methods within the whole landscape of structural biology techniques. It 
plays a crucial role, not only in determining high-resolution structures of 
macromolecules, but also in analyzing dynamic systems. In fact, it provides 
information about protein conformational equilibria, conformational changes upon 
binding to ligands, kinetic and thermodynamic aspects and functional dynamics of 
biomolecules, helping us to unveil the complex mechanisms by which biomolecules 
perform their multiple functions. However, as previously mentioned, the 
information obtained from these studies needs to be strictly correlated to that 
obtained from cell biology and biochemistry. For this reason, it is crucial that the 
data about a biomolecule are collected under conditions as close as possible to the 
physiological ones. The relatively recent progresses of NMR, in term of sensitivity, 
higher resolution, data acquisition and processing hardware and methodologies, 
make this structural technique one of the most efficient to achieve such 
requirements (Luchinat and Banci 2018).  In 2001, for the first time, a small isotope-
labelled globular protein was observed by NMR spectroscopy directly inside the 
cytoplasm of E.coli living cells (Serber and Dötsch 2001). That experiment was the 
milestone that gave birth to that branch of NMR spectroscopy called in-cell NMR. 
However, the use of bacteria to study human proteins presents some limitations. In 
the first place, bacterial machinery is not able to perform all those post-translational 
modifications that many human proteins require for a correct folding and to exerts 
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their natural function; secondly, the bacterial cytoplasm, in which  human proteins 
are over-expressed and analyzed, is not entirely comparable to that of eukaryotic 
cells; for example it lacks possible functional partners of the protein in exam 
(Luchinat and Banci 2017). Consequently, to overcome these problems, researchers 
have developed different methodologies that employed eukaryotic cells for in-cell 
NMR investigation. Initially, easily manageable eukaryotic cells, like Xenopus 
laevis oocytes, were used. In this approach, human isotope labelled proteins were 
first expressed and purified from bacteria, then inserted in the oocytes by the use of 
microinjections (Selenko et al. 2006; Sakai et al. 2006). Subsequently, other 
scientists started to deliver proteins directly inside human cells cytoplasm 
increasing the membrane permeability by cell-penetrating peptides, electroporation 
or streptolysin O (Theillet et al. 2016; Binolfi et al. 2016; Ogino et al. 2009; Inomata 
et al. 2009). Alongside the aforementioned methodologies, an approach that has 
proven its undoubted efficacy is the intracellular expression of proteins.  The 
challenges of this method were many, starting from the selection of appropriate 
eukaryotic cell lines, the design of an expression system capable of producing 
proteins at the high levels required by in-cell NMR, up the identification of the most 
efficient transfection technique. All of these challenges were overcome by several 
research groups who developed intracellular expression techniques using either 
yeast (Bertrand et al. 2012) or insect cells (Hamatsu et al. 2013) but more 
significantly  human cells (Banci et al. 2013; Barbieri, Luchinat, and Banci 2016). 
Thanks to the last improvements, in-cell NMR became the unique tool able to study 
macromolecules at atomic resolution within their native cellular environment. As 
the cells used in this approach are intact and alive, physiochemical parameters like 
pH, viscosity, redox potential, presence of molecular partners, are much closer to 
the physiological ones, and for this reason, the information obtained from the 
investigation about proteins structure and their dynamics acquire a greater 
relevance in the biological field (Luchinat and Banci 2018; Barbieri, Luchinat, and 







1.3 Protein-protein and protein-ligand interactions: strategies for their 
characterization and methodological advancements  
 
The majority of the biological processes as well as the metabolic reactions that take 
place inside the cells are the result of innumerable molecular recognition 
mechanisms that involve both protein-protein and protein-ligand interactions. 
These interactions not only underlie cellular life but also play a crucial role in the 
development of infections and pathological states. For this reason, their functional 
and structural characterization can be of vital importance to deepen their knowledge 
and thus to open the way to new therapeutic strategies. As mentioned above, 
solution NMR spectroscopy can play a crucial role in this type of investigation. 
However, one of its major limitations is the molecular size of the investigated 
proteins. In fact, increase in molecular weight determines faster transverse 
relaxation and therefore broader lines and faster magnetization decay. Furthermore, 
the higher number of nuclei contributes to increase the spectrum complexity. To 
overcome the latter problem, one of the mostly used approach is the segmental 
isotopic labelling that allows to isotopic label only a portion of the polypeptide 
sequence within the whole native and functional protein. This strategy is 
particularly suitable for the study of multi-domain proteins and large complexes 
because it permits to label only the protein fragment of interest with NMR active 
nuclei, thus simplifying the interpretation of crowded and overlapped NMR spectral 
regions (Xu et al. 1999). To date different segmental labelling techniques have been 
developed. The most commonly used are the expressed protein ligation (EPL), the 
sortase-mediated protein ligation, and the protein trans-splicing (PTS). EPL is a 
variant of the native chemical ligation (NCL) method (Dawson et al. 1994) and 
allows to ligate a synthetic peptide with a recombinant expressed protein (Berrade 
and Camarero 2009). Sortase-mediated protein ligation instead, is a technique that 
use the ability of a prokaryotic traspeptidase, the sortaseA. This enzyme recognizes 
a specific aminoacidic sequences (LPXTG) on the donor polypeptide and, through 
the cleavage between T and G residues is able to ligate carboxyl group of threonine 
to an amino group of a peptide with a N-terminal glycine (Debelouchina and Muir 
2018). The last segmental isotope labelling strategy, the PTS, exploits the catalytic 
properties of a polypeptide, known as intein, to self-excise from a host protein and 
ligate with a peptide bond the flanking polypeptide (Vila-Perelló and Muir 2010). 
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Among all these techniques, the latter is one of the most used in the NMR field. In 
fact, the PTS method can count on a wide range of inteins with different properties, 
from those that increase the expression yield to those capable of reacting in different 
temperature conditions and without too many constraints in the choice of extein 
junction site. In particular, the latter property can be extremely useful for NMR 
studies due to the possibility of obtaining a segmental labelled protein as close as 
possible to the native one. For this reason, PTS technique constitutes one of the 
most interesting strategies for studying large multi-domain protein and their 
interactions.  
NMR has been also proven to be extremely valuable in the characterization of 
protein-ligand interactions. Indeed, nowadays it is routinely used within another 
fundamental scientific area, i.e. the pharmaceutical sciences. Since the 1970s the 
number of articles in which the terms NMR coexist with “drug” or “inhibitor” has 
increased exponentially (fig. 1) (Sugiki et al. 2018). 
 
Fig. 1: Growth of the number of NMR papers related to the word “drug” and “inhibitor” (Sugiki et al. 2018) 
The number of NMR papers related to “inhibitor” 







The number of NMR papers related to “drug” 











Ligand-binding validation or identification of potential inhibitors can be obtained 
just using basic NMR parameters and approaches (fig. 2). For example, the high 
sensitivity of the chemical shifts to perturbations around the observed atoms can 
provide useful information about whether a small molecule binds to a target protein 
or nucleic acids and also which residues or functional groups are involved in this 
interaction (Pellecchia et al. 2008). The  overall mobility of the ligands  differs 
significantly from the free to the bound state; this is easily detectable through the 
saturation transfer difference analysis (Mayer and Meyer 1999) or simple 1H NMR 




Fig. 2: Overview of applications of NMR in drug screening (Pellecchia et al. 2008) 
 
However, further improvement in the development and identification of new drugs 
can be achieved through the use of in-cell NMR. In this way, by testing a potential 
drug directly in the cell, information on its behavior in physiological conditions and 























2.1 Segmental isotope labelling approach for the study of multidomain 
proteins: its application to the characterization for the Copper Chaperone for 
SOD1 (CCS) 
 
2.1.1 SOD1-CCS overview 
 
Superoxide dismutases (SOD) are well-characterized metalloproteins which, by 
exerting an antioxidant role, protect cells from the possible damages caused by 
superoxide anion. This function was first described in 1969 by McCord and 
Fridovich that discovered how these enzymes are able to dismutate superoxide 
anion to oxygen and hydrogen peroxide (McCord and Fridovich 1969): 
 
2O#$ 	+ 	2H(	®	O# 	+	H#O#  
 
Superoxide dismutases family members can be roughly divided in groups according 
to the folding and to the metal cofactor: Cu/Zn-SOD, Mn-SOD, Fe-SOD and Ni-
SOD. The human isoforms are three: SOD1 (Zn/Cu) that has been analyzed in this 
thesis, SOD2 (Mn) which is located in the mitochondrial matrix and the 
extracellular form SOD3 (Zn/Cu). SOD1 is largely present inside mammalian cells 
cytoplasm but also in the mitochondrial inter-membrane space, where it can directly 
remove the superoxide that is formed as a byproduct of the respiratory chain 
(Okado-Matsumoto and Fridovich 2001). The relevance of SOD1 has progressively 
increased due the discovery of the correlation between some mutations on its 
sequence and cases of familial Amyotrophic Lateral Sclerosis (fALS) (Luchinat, 
Barbieri, and Banci 2017). ALS is a fatal neurodegenerative disease that 
progressively brings to the destruction of the motoneurons of the spinal cord, brain 
stem and cortex with consequent muscular paralyses (Rowland and Shneider 2001). 
90-95% of ALS cases have been shown to be sporadic (sALS), while the remaining 
5-10% are linked to a previous family history of the disease (fALS). Of these, 20-
25% are attributable to mutations mapped on the SOD1 encoding gene located on 
chromosome 21 (Valentine, Doucette, and Zittin Potter 2005). The development of 
fALS is not caused by a loss of functionality of the enzyme, but by a gain of toxicity. 
Indeed, SOD1 knock-out mice do not develop the disease and moreover, many 
fALS mutant SOD1 proteins maintain a high level of enzymatic activity (Rabizadeh 
et al. 1995; Borchelt et al. 1994; Reaume et al. 1996). The presence of proteinaceous 
aggregates rich in SOD1 in the case of ALS patients or rich in other proteins in the 
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case of Alzheimer, Parkinson, Huntington, transmittable spongiform 
encephalopathies, and others, is a common feature of many neurodegenerative 
diseases (Bruijn, Miller, and Cleveland 2004). This suggests a correlation between 
this SOD1-rich aggregates and the pathology (Bruijn et al. 1998). However, as for 
the other pathologies cited above, it is currently believed that these inclusions are 
not the main toxic species themselves, also because they appear at a relatively 
advanced stage of the disease (Bitan et al. 2003; Sherman and Goldberg 2001; 
Lashuel et al. 2002). Some of these fALS mutations are known to negatively affect 
the nascent superoxide dismutase stability, with consequent difficulties of reaching 
the mature form and then leading to the formation of aggregates (Lindberg, Tibell, 
and Oliveberg 2002; Hayward et al. 2002). The process of maturation by which 
SOD1 achieves its final enzymatic-active form is a concerted pattern of molecular 
events that have been extensively studied. At first, apo-SOD1, in its monomeric 
disulfide-reduced form, spontaneously binds zinc to form a stable homodimer, then 
copper-transfer and disulfide bond formation between the Cys57 and the Cys146 
occur, mediated by a metallochaperone termed Copper Chaperone for SOD1 (CCS) 
(Arnesano et al. 2004; Banci et al. 2006; Schmidt et al. 1999; Casareno, Waggoner, 
and Gitlin 1998). CCS is widely expressed all over the eukaryotic organisms and 
shares with SOD1 a comparable distribution in the various cellular compartments 
(Rae et al. 1999; Rothstein et al. 1999). This chaperone also forms a homodimer, 
each monomer being constituted by three domains each of them with a specific 
crucial role in the SOD1 maturation process. The N-terminal domain (D1) is 
essential for copper delivery in vivo, it has a high fold similarity with other 
metallochaperones and shows the typical MXCXXC copper binding motif 
(Caruano-yzermans, Bartnikas, and Gitlin 2006). The second domain (D2) 
possesses a high structural and sequence similarity with SOD1 and, due to its SOD-
like conformation, is able to interact  with the immature form of the molecule 
(Schmidt et al. 1999; Lamb et al. 1999, 2000). The C-terminal domain (D3) is a 
short polypeptide segment (30-40 residues) that natively lacks secondary structure. 
It harbors invariant conserved CXC (Cys-244 and Cys-246) motif that appears to 
be essential for the correct SOD1 maturation (Furukawa, Torres, and O’Halloran 
2004). Despite many efforts made to elucidate the CCS-dependent SOD1 
maturation mechanism, some aspects of this multi-steps molecular process remain 
still unknown. For example, the mechanism of disulfide bond formation, whether 
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the copper transfer and disulfide bond formation occur in a single step or in different 
moments, and the exact conformation adopted by the D3 in the SOD1-CCS 
heterodimer, have remained elusive until now. In one of the most accredited model, 
the CCS-mediated SOD1 activation takes place in at least six steps (fig. 3): zinc 
acquisition, formation of the CCS heterodimer with SOD1, copper delivery from 
CCS to SOD1 thanks to D1, disulfide bond transfer from CCS (Cys244-Cys246) to 
SOD1 (Cys57-Cys146) probably via the CCS (Cys244) and SOD1 (Cys57) inter-
molecular disulfide bond formation, dimerization of SOD1 (Banci et al. 2012). 
 
 
Fig. 3: Schematic mechanism of CCS-dependent SOD1 maturation in vitro. (1) Nascent SOD1 (E,E-SODSH) 
acquires zinc producing E,Zn-SOD1SH. (2) The SOD1SH monomer forms a heterodimer with a monomer Cu(I)-
CCS. The current study suggests that copper transfer (3) occurs before formation of the intermolecular (4), and 
then SOD1 intramolecular (5), disulfide bond, resulting in the mature monomer (6) that dimerizes to the active 
state. Although oxygen in vitro is required in the process before step 4, it is currently unknown precisely at 
which step this occurs. [Note: E,Zn-SOD1SH can obtain Cu(I) in a CCS-independent manner]. (Banci et al. 
2012) 
 
According to the above mechanism, CCS D1 is responsible for copper delivery, D2 
is required for the interaction with SOD1 and D3 is involved in the disulfide bond 
formation. However, other studies revealed conflicting results. In fact, a series of 
experiments conducted to examine the roles of the various CCS  domains at a 
cellular level reported that in cells transfected with full length CCS containing a 
mutation on the D3 CXC-binding site neither SOD1 activity nor SOD1 copper 
acquisition were observed (Caruano-yzermans, Bartnikas, and Gitlin 2006). 
Moreover, different organisms like Drosophila melanogaster, Anopheles gambiae 
 
 12 
and Saccharomyces pombe, lacking the MXCXXC motif in the first domain, show 
to have the ability to bring SOD to a complete maturation despite the absence of the 
copper chaperone activity (Kirby et al. 2008; Laliberté et al. 2004).  
To underline even more the CCS relevance, it has been recently demonstrated by 
in-vitro and in-cell NMR analysis, that the second domain of CCS co-expressed 
with a set of SOD1 fALS mutants helps the nascent SOD1 to bind zinc, stabilizes 
its structure, and addresses it towards the right maturation pathway, therefore acting 
as a molecular chaperone (Luchinat, Barbieri, and Banci 2017). Overall, CCS is 
responsible of many molecular events and is a closely related to the pathological 
states in which SOD1 mutants are involved. Because of this reason, CCS deserves 
further and in-depth investigations that may shed light on its still obscure aspects.   
 
2.1.2 Aims of the study  
 
The aim of this project consisted in using nuclear magnetic spectroscopy (NMR) to 
characterize CCS D3 conformation within full-length CCS, in different metalation 
and redox states, both in the CCS homodimer and in the heterodimer with SOD1. 
The application of a segmental labelling technique would allow the incorporation 
of NMR active nuclei only in the CCS D3 making easier the study of all its possible 
conformations through to the analysis of the backbone chemical shifts, thanks to 
the reduced spectral crowding. 
 
2.1.3 State of the art 
 
The structural features of the CCS third domain have been the subject of numerous 
studies over the years. The lack of secondary structure gives this domain a high 
level of flexibility allowing it to assume radically different conformations in 
solution. This has been further confirmed by a study of Fetherolf et al. in 2017. The 
authors reported a hSOD-yCCS heterodimer x-ray structure in which the D3 
conformation strikingly differs from that reported for  the same domain in the 








Figure 4. Superposition of ySOD-yCCS (Lamb et al. 2001) and hSOD1-yCCS (Fetherolf et al. 2017) 
 
 
In this new structure it is evident that CCS D3 takes a β-hairpin shape, which is in 
contrast with the disordered and/or α-helix conformations observed in earlier works 
(Lamb et al. 1999, 2001). The β-hairpin is stabilized by several interactions with 
residues of SOD, of D1, and of D2 that further contribute to strengthen the entire 






Figure 5. D3 β-hairpin interaction with SOD1 β-barrel and disulfide loop. Cys57–Cys146 Sod1 disulfide bond 
exposes an electropositive zone near Cys146. CCS D1 (blue) and D2 (gray) are represented as surfaces and the 
stabilizing positioning of residues Trp222 and Trp237 from CCS D3 are highlighted. (Fetherolf et al. 2017) 
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Large multi-domain protein complexes investigation has always represented a 
challenge for solution NMR spectroscopy. In solution, CCS is present as a 
homodimer, and this means that its size and the numerous interactions between 
domains make its study via NMR challenging. Therefore, to overcome these 
problems, we sought to apply the segmental labelling technique known as protein 
trans-splicing (PTS). This kind of approach basically consists in a post-translational 
modification catalysed by an intervening polypeptide sequence termed intein. Intein 
is able to excide itself out from a precursor protein and to ligate the flanking 
polypeptide sequences, termed exteins, with a native peptide bond. As in this 
research project, intein can also be split into its N- and C-terminus regions. In this 
case the two separate intein parts individually have no activity but once combined 
they associate noncovalently to give a functional protein splicing element followed 
by the ligation between N- and C- extein sequences constituting the full-length 
protein (fig. 6). A fundamental requirement for successful ligation is the presence 





Figure 6. Protein trans-splicing scheme (Mootz 2009). Intein is divided in its N- and C- terminus portion (IntN 
and IntC) and conjugated with extein N- (ExN) and extein C- (ExC) protein domains. After the non-covalent 
association between IntN and IntC a series of reaction bring to the formation of a native peptide bond between 
exteins and to the detachment of the intein portions.  
 
The incorporation of isotope labels only in the CCS D3 region will overcome the 
problem of its non-dispersed signals overlapped with those of the other two 
domains, thus providing an easier analysis of that particular spectral region. The 
experimental plan included different steps (fig. 7): the first one consists of the 
separate expression of unlabelled CCS D1D2 and [13C 15N] labelled CCS D3 ligated 
respectively with intein N- and C-terminus sequences, a second step consists in 
reconstituting the full-length CCS through the trans splicing reaction between the 
previous expressed constructs, while the last step is the NMR investigation of both 
CCS homodimer and heterodimer with SOD1. In the first part of this work, among 
all the various types of inteins, we decided to use those of a unicellular 
microorganism known as Nostoc punctiforme. Such inteins showed to have a high 
efficiency in various conditions combined with a high tolerability of the extein 
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To achieve the final goal, three different experimental approaches have been 
adopted: 
 
Cloning and ligation: 
N- and C-terminus intein sequences, CCS D1D2 domain and CCS D3 domain were 
first amplified separately trough PCR, then, the ligase enzyme was used to 
constitute D1D2-InteinN and InteinC-D3 constructs (fig. 8 a-b). Finally, the 
obtained fragments were cloned in two PET11 vectors for the expression. 
                  
 
 
Fig. 8 Electrophoresis gels of fragments a) D1D2-InteinN (1023 bp) and b) InteinC-D3 (255 bp) 
 
Although the electrophoresis gels reported in fig. 8 showed the presence of bands 
corresponding to the correct height of the two constructs, the sequencing data 
revealed that cloning and ligation were not correct. Indeed, both IntN_D1D2 and 
D3_IntC constructs lacked of some bases in the blunt ligases zone.  
Multiple cloning attempts trying to variate annealing temperature and testing 
different DNA/plasmid ratio were performed with no success. We hypothesized that 
the problem was due to some intrinsic property of our protein rather than to the 
cloning technique itself. For this reason, we designed a different construct which 
was purchased as de-novo synthetized. 
 
Constructs synthesis 
D1D2-IntN and IntC-D3 constructs were de novo synthesized following the scheme 
represented in fig. 9 and then cloned in PET11 expression vector between BamH1 
and Nde restriction sites. The last CCS-D1D2 fragment residue was mutated from 
an Arg to a Cys, as a fundamental requirement for the correct happening of the 












Figure 9. Schematic representation of the two synthetized constructs. We can find the 6-His tail purification 
tags (green), the two recombinant constructs (blue) and the cysteine residue at the splicing junction (orange). 
 
The purification, performed through a His trap column, showed a poor yield in the 
soluble fraction and a low level of purity for both the expressed proteins, but, 
despite these problems, we considered that the amount of products was sufficient 




Figure 10. SDS-page gel of protein trans splicing reaction between the two constructs 
 
In the SDS-page of the PTS reaction (fig. 10) we could identify bands 
corresponding to D1D2-IntN (37 kDa), IntC-D3 (9 kDa), IntC (4,9 kDa) alone and 
FL-CCS (29 kDa). Instead, IntN (12 kDa) fragment was not clearly visible. The 
progressive reaction product formation was also visible in the western blot (WB) 
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From both SDS page and WB the formation of the FL-CCS was clear, but resulted 
in a very poor yield, not sufficient for an NMR experiments. The PTS reaction was 
repeated in different conditions of temperature (25°C, 30°C and 37°C) and 
concentration of the two precursors (from ~20 to ~50 µM). However, the results 
remained unsatisfactory. Furthermore, IntC-D3 fragments seemed to show a 
progressive hydrolysis during the course of the reaction. To overcome these 
problems and to be able to recover even the insoluble part of the two constructs, 
further attempts were made taking in account a previous publication (Zettler, Schütz, 
and Mootz 2009), in which it was reported that the PTS reaction could take place 
even in presence of different urea concentrations. According to the aforementioned 
paper, pellets of expression cultures were resuspended in urea 8 M solution and 
purified under denaturing conditions. The buffer of the two proteins was then 
diluted to a 4 M urea concentration and the PTS reaction was performed mixing 
equimolar amounts of the precursors. However, no formation of the final product 
took place (fig. 12). A better result was not even achieved by refolding the 
precursors through a multi-steps dialysis in decreasing urea concentration and then 
testing PTS reaction with higher precursors concentration (~100 µM). 
         
 
Figure 12. Protein trans splicing reaction SDS-page gel under denaturing condition (UREA 4M). It is possible 
to identify bands corresponding to D1D2-IntN (37 kDa) and IntC-D3 (9 kDa).  
 
Multiple further attempts testing various solutions and trying to optimize every step 
of the entire experimental workflow, from the conditions of expression, purification 
to those of reaction were made. NaCl different concentrations (from 150 mM to 1 
M) as well as various reducing agents (TCEP and DTT) were tested both in 
















levels was observed. Furthermore, two types of Superdex prep grade columns were 
used for the gel filtration step, the Superdex 16/60 75 pg and the Superdex 16/60 
200 pg, to test different separation resolutions. Despite these numerous attempts the 
expected results have not been achieved. In fact, we had to face several critical 
issues including a poor solubility of D1D2-IntN and IntC-D3 expressed proteins, 
difficulty in purification and an insufficient protein trans splicing reaction yield. In 
order to overcome these problems, we decided to redesign the constructs.  
 
New constructs design 
New constructs were designed following a scheme kindly suggested by Prof. 
Gaetano Montelione in order to improve both the solubility and the specificity of 
the reaction. The most important change concerned the type of inteins used. Indeed, 
the constructs design involved the use of a chimeric split intein system since the 
two catalytic polypeptides derived from two different organisms. The N-terminal 
part of the intein came from the Nostoc punctiforme DnaE gene while the C-
terminus from the Synechocistis sp. DnaE gene. The use of this inteine system also 
required the insertion of a specific recognition sequence composed of SGV 
aminoacidic residues in the trans-splicing junction (Lockless & Muir, 2009). Both 
fragments were conjugated with maltose binding protein (MBP) to improve the 
solubility and a tobacco etch virus cleavage site was introduced to eliminate MBP 
and StrepII purification tag from the reconstituted FL-CCS. In figure 13 the scheme 




Figure 13. Schematic representation of the two new synthetized constructs. We can find the purification tags 
(green), the two recombinant constructs (blue), the SGV motif at the splicing junction (orange), the maltose 
binding protein (red) and the TEV cleavage site (white).  
 
The first tests, unlike what we saw with the previous constructs, confirmed for both 
D1D2-IntN and Int-D3 a higher expression efficiency with the major part of the 
expressed protein located in the soluble fraction. PTS reaction was then performed 









observed a progressive reduction of the precursors and the formation of a ~75 kDa 
band corresponding to the final expected product, i.e Strep-MBP-FL-CCS-His-tag 
(fig. 14).  
 
         
 
   
 
Figure 14. SDS-page gel performed on the PTS mixture with withdrawals at different time. It is possible to 
identify bands corresponding to Strep-MBP-TEV-CCS_D1D1-IntN (82.66 kDa), Strep-MBP-TEV-FL-CCS 
(75.43 kDa) and MBP-IntC-CCS_D3_SGV (51.57 kDa).  
 
The reaction solution was purified using a His-trap nickel affinity column, and a 
small aliquot was incubated over-night (ON) at room temperature with TEV 
enzyme to obtain a FL-CCS without any additional tags (fig. 15 a-b). 
 
 
Figure 15. SDS-page gel performed on a) fractions collected from the purification through His-trap affinity 
column of the PTS reaction mixture and on b) aliquot collected from the previous purification before and after 
the cut with TEV enzyme. It is possible to identify bands corresponding to Strep-MBP-TEV-CCS_D1D1-IntN 
(82.66 kDa), Strep-MBP-TEV-FL-CCS (75.43 kDa), MBP-IntC-CCS_D3_SGV (51.57 kDa), Strep-MBP-TEV 














































The success of the PTS reaction was confirmed by the occurrence of the TEV cut 
with the formation of FL-CCS as shown in figure 14b. However, despite the results 
of the reaction, its purification constituted a challenging aspect. In fact, as already 
observed in the previous experimental approach, we observed the formation of 
aggregates that interfered with the purification procedures, thus making impossible 
to achieve a sufficient level of purity. To solve this problem we applied different 
techniques, from gel filtration to anionic exchange assays. Furthermore, we tried 
different purification buffer compositions increasing NaCl concentration up to 2M 
in order to break any hydrophilic interactions. However, in none of these attempts 
it was possible to reach sufficiently high levels of purity to perform NMR 
experiments.  
Further attempts will be made to purify the PTS reaction mixture under denaturing 
conditions (UREA 8M). As next step, the protein will be refolded and then we will 




In the present work, the segmental labelling technique known as protein trans 
splicing was applied for the purpose of elucidating the conformational features of 
the CCS third domain in its homodimeric form and in the heterodimer with SOD1.  
Three different experimental strategies were followed, among which the last one 
revealed to be the most promising. In fact, the refined constructs optimization, 
obtained through the insertion of the SGV recognition sequence, the choice of high 
efficiency inteins as well as the use of the MBP solubility tags, allowed to improve 
both the expression and the PTS reaction yield with the formation of the final 
expected product, i.e. FL-CCS.  Although these results are encouraging, there are 
still two crucial problems that we need to overcome. The first one regards the 
incomplete reaction between the two precursors while the second is the difficulty 
of obtaining a final product that is sufficiently pure to be analysed by NMR. 
Multiple issues can negatively affect the expected results. For example,  cases of 
N- and/or C-cleavages (fig. 16) during the occurrence of PTS reaction are reported 




Figure 16. N- and -C possible cleavages during the PTS reaction 
 
The authors explained these off-pathway cleavage reactions as due to a perturbation 
of the inteins catalytic core by foreign extein sequences, resulting in the loss of N- 
or C- extein before the splicing reaction is completed. Moreover, it is necessary to 
take in account the splicing sequence junction nature. In particular, both the residues 
flanking the N-terminus and C-terminus catalytic sites and the same junction length 
can be crucial for the effective occurrence of the reaction. However, considering 
the results obtained until now a possible common cause for the main problems 
encountered emerges, that is the tendency of the two fragments to be prone to form 
aggregates. In fact, it is well known that CCS D2 is essential for the formation of 
the homodimer in solution and therefore, it is possible that these strong interactions 
can prevent both the splicing reaction and the subsequent purification.  
The segmental labelling technique known as protein trans-splicing has never been 
developed for studying the CCS third domain and its interaction with SOD1. For 
this reason, all the applied protocols need a refined optimization process in order to 








2.2 Protein based NMR drug screening in human living cells: its application to 





Nuclear magnetic resonance spectroscopy has been shown to be an extremely 
powerful method for studying protein-ligand interactions, and, nowadays, with the 
implementation of in-cell NMR, there has been a further step towards probing these 
processes in living human cells. The information obtained from the application of 
this method can be crucial not only to improve the potency and the efficacy of drugs 
but also to better understand their action mode in the physiological context. In this 
research project, we showed how in-cell NMR can be applied in a novel manner to 
overcome some bottlenecks that are typical of the classical drug discovery pipeline 
in vitro. Indeed, it is very common that many promising drugs that have undergone 
a long optimization procedure in vitro turn out to be totally ineffective in vivo. In 
this work we applied NMR spectroscopy to analyze the binding of carbonic 
anhydrase inhibitors to the second isoform of the human carbonic anhydrase (CA 
II) directly in the cytosol of living human cells. 
 
 
2.2.2 Carbonic anhydrase II 
 
Carbonic anhydrases (CAs) are enzymes that catalyse the reversible hydration of 
carbon dioxide and bicarbonate:  
 
CO# 	+	H#O		 ↔ 		HCO+$ 	+	H(  
 
These enzymes have been known for over 80 years, and since their discovery in 
1933, they have been the subject of numerous studies that embraced different 
research disciplines, from structural biology, to clinical sciences and drug discovery. 
There are five different classes in which CAs are divided: a, b, g, d and z. a-class, 
the only present in mammals, comprises CAs primarily present in vertebrates. The 
b family is found in higher plant chloroplasts and some prokaryotes, g is 
characteristic of archaebacteria, especially methanogens, whereas d and z are 
commonly observed in diatoms and some bacteria. These classes are considered to 
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be a clear example of convergent evolution, in fact, they present differences in 
primary sequence of amino acids and as consequence in the three-dimensional 
tertiary structure (a, b, g). This implies that they have convergently evolved to carry 
out the same biochemical reaction essential for life (Frost 2014). Among all classes, 
the a is definitely the most known and deeply studied due to its implications in 
numerous human pathologies. It consists of sixteen different isoforms which are 
distinguished by function, localization, tissue-specific expression, kinetic 
properties and sensitivity to inhibitors (Supuran 2008). Of these, eight are cytosolic 
proteins (CA I, CA II, CA III, CA VII, CA VIII, CA X, CA XI, CA XIII), two are 
localized in the mitochondrial matrix (CA VA, CA VB), CA VI is secreted. Finally, 
five isoforms take contact with cellular membrane, among which CA IX, CA XII 
and CA XIV are transmembrane proteins, whereas CA IV and CA XV are 
glycosylphosphatidylinositol (GPI)-anchored proteins (Frost 2014). All these 
isoforms are involved in a myriad of physiological processes like transport of CO2 
and HCO3- across both membrane sides, acid-basic balance, signal transduction, 
oncogenesis, cellular proliferation, secretion and others that have been well 
documented along many decades of study (Ditte et al. 2011; Thiry et al. 2006; 
Henry 1996; Sterling, Reithmeier, and Casey 2001a).   
In this project we focused on carbonic anhydrase II (CAII) isoform. CAII is highly 
expressed in red blood cells (RBCs) and in the kidney intercalated cells, but it can 
be present at lower levels also in loop of Henle and in proximal tubules 
(Chegwidden and Carter 2000; Swenson 2000; Brown et al. 1983). The role of this 
enzyme is to control cytosolic pH balance. This balance is maintained through the 
transport of CO2 out of the cell and also through the interaction that this enzyme 
establishes with different membrane carriers, among which, Cl-/HCO3- and Na+/H+ 
exchangers and the Na+/HCO3- cotransporter (Vince and Reithmeier 1998, 2000; 
Sterling, Reithmeier, and Casey 2001b; Becker and Deitmer 2007; X. Li et al. 2002). 
Structurally, CAII presents an active site in which a Zn2+ ion is coordinated to three 















Fig. 17: Structure of human CAII; represented in cartoon the active site of CAII with three His residues that 
coordinate a Zn2+ ion (in grey). PDB: 3KS3.  
 
The overall catalytic pocket is constituted by two different portions, one hydrophilic 
and the other hydrophobic, with the last one comprising the CO2 binding site.  
CA II in particular is associated with cases of epilepsy and glaucoma and it is still 
the subject of numerous studies aimed at developing new and increasingly specific 
drugs. However, all CAs share a high structural similarity of the catalytic pocket 
thus limiting the isoform specificity of drugs and, as consequence, the possibility 
of treating pathologies in a selective fashion.  
The profound knowledge of this isoform and the numerous drug design studies and 
already approved and used drugs, as well as the ease of expression in human cells 
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Abstract: Structure-based drug development is often ham-
pered by the lack of in vivo activity of promising compounds
screened in vitro, due to low membrane permeability or poor
intracellular binding selectivity. Herein, we show that ligand
screening can be performed in living human cells by “intra-
cellular protein-observed” NMR spectroscopy, without requir-
ing enzymatic activity measurements or other cellular assays.
Quantitative binding information is obtained by fast, inex-
pensive 1H NMR experiments, providing intracellular dose-
and time-dependent ligand binding curves, from which kinetic
and thermodynamic parameters linked to cell permeability and
binding affinity and selectivity are obtained. The approach was
applied to carbonic anhydrase and, in principle, can be
extended to any NMR-observable intracellular target. The
results obtained are directly related to the potency of candidate
drugs, that is, the required dose. The application of this
approach at an early stage of the drug design pipeline could
greatly increase the low success rate of modern drug develop-
ment.
Rational drug design requires ligand-based screenings and
protein-based structural studies to characterize the binding to
the target protein, followed by lead optimization to increase
the binding constant. The ability to reach intracellular targets
must then evaluated with ad hoc cell-based assays. Most drug
candidates fail here or at later stages, due to lack of activity in
cells or to the occurrence of adverse effects in vivo.[1] Such
failures are often linked to poor membrane permeability and/
or to the lack of binding specificity in the cellular environ-
ment. Nuclear magnetic resonance (NMR) spectroscopy
applied to living cells[2–6] has the potential to overcome
these critical bottlenecks, as it can directly observe macro-
molecule–ligand interactions at atomic resolution within the
cellular environment.[2, 7,8] Herein, we report an approach to
perform protein-observed ligand screening by NMR directly
in the cytosol of living human cells. The approach allows the
assessment of membrane permeability and intracellular bind-
ing specificity of candidate drugs, which cannot be inferred
from in vitro analysis, and can reveal interesting and strikingly
different behaviour for compounds that have similar proper-
ties in vitro.
We applied the method to the screening of inhibitors of
the second isoform of human carbonic anhydrase (CA2). In
humans there are 15 CA isoforms,[9] many of which are
relevant drug targets involved in several pathologies.[10–14] To
date, several CA inhibitors are routinely administered in the
treatment of glaucoma, epilepsy, or as diuretics,[15, 16] with
some of them in clinical development as antitumor
agents,[17,18] In order to detect CA2 by NMR, the protein
was directly expressed and labelled in the cytosol of human
cells (see the Experimental Methods section of the Support-
ing Information).[19,20] NMR signals arising from [15N]-CA2
were clearly detected in the 1H-15N correlation spectra
(Supporting Information, Figure S1), indicating that the
intracellular protein is soluble and free from interactions
with slow-tumbling cellular components, which would other-
wise increase transverse relaxation and cause signal broad-
ening beyond detection.[21] Signals from slow-exchanging
histidine side chain amide protons located in the active site
were clearly detected in a background-free region of the 1D
1H NMR spectrum between 11 and 16 ppm, allowing protein–
ligand interactions to be monitored without the need for
isotopic labelling (Supporting Information, Figure S2).
The interaction between intracellular CA2 and two
approved drugs, acetazolamide (AAZ) and methazolamide
(MZA), was monitored by 1H-15N NMR. Spectra from cells
expressing [15N]-CA2 treated with excess of AAZ or MZA
showed clear differences compared to untreated cells, indi-
cating that both drugs had bound the intracellular protein
(Figure 1a,b). Inhibition of intracellular CA2 was confirmed
by total CO2 hydration activity measured by stopped-flow,
which was largely decreased in lysates from cells expressing
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CA2 treated with inhibitor with respect to untreated cells
(Supporting Information, Figure S3). In vitro, titration of
CA2 with one equivalent of AAZ or MZA resulted in
quantitative binding (Supporting Information, Figure S4),
consistent with nanomolar dissociation constants (KdAAZ =
12.5! 1.0 nm ; KdMZA = 14! 0.9 nm, see the Experimental
Methods section in the Supporting Information). The pro-
tein–ligand interaction can be mapped at the single-residue
level by chemical shift perturbation (CSP) analysis. The high
similarity between in-cell and in vitro CSP plots revealed that
both ligands bind to intracellular CA2 in an almost identical
fashion as in vitro (Supporting Information, Figure S5), that is
also consistent with the atomic structure of the protein–drug
adducts reported previously (Figure 1d).[22]
Binding of AAZ and MZA to unlabelled CA2 in the slow
exchange regime was clearly observed in the imino region of
the 1D 1H NMR spectra, both in cells and in vitro, due to the
proximity of the observed nuclei to the ligand binding site
(Figure 1c,d and Supporting Information, Figure S6 a,b).
Despite their known pH-dependence, these nuclei proved to
be excellent reporters of the free and bound states of CA2
(Supporting Information, Figure S6 c). The surprisingly good
signal separation between free and bound states, despite the
broader spectral lines of in-cell NMR spectra, allowed the
area under each peak to be retrieved by deconvolution
analysis (Supporting Information, Figure S7). Simple 1D
1H NMR spectra could therefore provide a quantitative
measure of the free and ligand-bound fractions of intra-
cellular CA2, providing a less time- and cost-intensive
strategy compared to 2D 1H-15N NMR.
1H in-cell NMR and deconvolution analysis were sub-
sequently applied to screen a larger set of CA inhibitors,
selected among recently reported sulfonamide-derivatives,
for which the binding affinity to CA2 had been previously
characterized in vitro and ranged from low-nanomolar to
high-micromolar (Figure 2).[23–25] To establish whether this
approach could discriminate ligands based on their cell
permeability, a CA inhibitor (C18) that is unable to diffuse
through the plasma membrane was also included. Strikingly,
Figure 1. Overlay of 1H-15N NMR spectra of cells expressing [15N]-CA2 in the absence of ligands (black) and treated for 1 hour with a) 100 mm AAZ
(red); b) 100 mm MZA (magenta). Some peaks shifting upon ligand binding are labelled. c) Imino region of the 1D 1H NMR spectra of unlabelled
intracellular CA2 in the absence of ligands (black) and bound to AAZ (red) or MZA (magenta). Peaks used to obtain binding curved are marked
with arrows. d) Active site view of CA2/AAZ complex (PDB 3HS4): the catalytic zinc ion (orange sphere) is located at the end of a large, conical
cavity close to the protein centre and exhibits a tetrahedral coordination with three conserved histidine residues and, in the active form, a water
molecule/hydroxide ion as fourth ligand.[9] The latter is replaced by the deprotonated sulfonamide nitrogen in the enzyme/inhibitor adduct. The
SO2NH
" moiety is additionally H-bonded as donor to the OH moiety and as acceptor to the amidic NH of residue Thr199.
Figure 2. Sulfonamide-derived CA inhibitors analyzed in this study. KI
measured in vitro for CA2 are reported (see the Experimental Methods
section of the Supporting Information).
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two categories of ligands emerged, that did not correlate with
the differences in binding affinity: those that bind intra-
cellular CA2 quantitatively, similar to AAZ and MZA (1, 3,
and 4, Figure 3), and those for which binding is negligible,
similar to C18 (2, 5, 6, 7, and 8, Supporting Information,
Figure S8). In comparison, ligand binding was clearly
observed in vitro, both in the 1H-15N and in the 1H NMR
spectra (Supporting Information, Figure S9).
Therefore, a simple high-dose ligand screening by 1H in-
cell NMR could discriminate between “successful” and
“unsuccessful” inhibitors without recurring to any cell-based
activity assay, by directly observing intracellular binding.
However, no insights were provided on the reasons why some
ligands, even those with high in vitro affinity, do not bind
intracellular CA2 at all. While several phenomena could
prevent a ligand from binding an intracellular target, the most
likely reasons are a low permeability of the plasma membrane
and a low binding specificity to the target, that is, the presence
of other intracellular molecules with comparatively high
affinity for the same ligand. To provide a mechanistic
hypothesis on the behaviour of the “unsuccessful” ligands,
the “successful” ligands were analysed by in-cell NMR in
a dose- and in a time-dependent manner. First, cells express-
ing CA2 and treated for 1 hour with increasing concentrations
of each ligand were analysed by 1H in-cell NMR and spectral
deconvolution. Except AAZ, all the ligands followed
a common trend, showing incomplete binding at low doses
and reaching complete binding at around 5–15 mm (Fig-
ure 4a–e). At the lowest ligand concentrations, the incom-
plete binding may be due to a lower-than-one ligand to CA2
molar ratio. Surprisingly, AAZ resulted in a much shallower
dose-dependent binding curve, showing no binding below
10 mm and complete binding only around approximately
75 mm. Incomplete binding of AAZ at higher molar ratios
suggests that it either diffuses slowly through the plasma
membrane or strongly binds to other intracellular molecules.
While competition binding is an equilibrium effect, slow
diffusion kinetics should be observed in time-dependent
binding experiments at fixed ligand concentration. Indeed,
treating the cells with either 27 mm AAZ or 2 mm MZA for
increasing time periods resulted in clear time-dependent
Figure 3. Imino region of the 1D 1H NMR spectra of cells expressing
CA2 in the absence of ligands (black) and treated with 100 mm of each
ligand for 1 hour, showing complete binding to intracellular CA2: AAZ
(red), MZA (magenta) and ligands 1, 3, 4 (blue). Peaks used to obtain
binding curves are marked with arrows.
Figure 4. a–e) Dose-dependent binding curves observed in cells expressing CA2 treated for 1 hour with different ligands at increasing
concentrations, fitted with a time-dependent binding equilibrium (See the Experimental Methods section of the Supporting Information). Each dot
represents the area under a single peak in the imino region of the 1D 1H in-cell NMR spectra, normalized to the total spectral area.
f) Dissociation constant measured in vitro (Kd), permeability coefficient ! membrane area (Kp A) obtained from curve fitting and predicted skin
permeability coefficient (logKp) for each molecule. “Unsuccessful” molecules correlate with lower skin permeability (shown in bold).
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binding curves (Figure 5). Dose- and time-dependent curves
could then be fitted with a kinetic model to obtain membrane
permeability coefficients, revealing that AAZ diffuses
approximately 12-fold slower than MZA (Figure 4 f). As
both molecules passively diffuse through the plasma mem-
brane and do not rely on active transport,[26] such strikingly
different behaviour should eventually affect drug permeabil-
ity in human tissues. Indeed, the observed difference is
reflected in the pharmacokinetic properties of the two drugs,
as the recommended dosage for AAZ in the treatment of
glaucoma is approximately 10-fold higher than that of
MZA.[27] Therefore, the kinetics of membrane diffusion can
greatly affect the behaviour of different ligands, irrespective
of their binding affinity for the intracellular target. Interest-
ingly, all the “unsuccessful” ligands screened here share
a nitrogenous base, either a uracil (2, 6, 7, and 8) or adenine
(5) as a common feature, and have a much lower predicted
skin permeability than the “successful” ligands (Figure 4 f),
thus suggesting that the lack of binding of the former is likely
the consequence of an exceedingly slow diffusion through the
plasma membrane.
Once the cells are analysed under steady-state conditions,
that is, after the ligand had enough time to reach the
intracellular target, the in-cell binding curve can be fitted to
obtain an apparent Kd. Comparison with the Kd determined
in vitro would reveal the extent of competition binding,
thereby providing a measure of intracellular binding specific-
ity. To obtain a meaningful apparent Kd, the ligand to protein
molar ratio should be higher than one. For this purpose, useful
binding curves can be obtained from cells expressing the
target protein at lower levels. Indeed, cells expressing an
approximately 3-fold lower level of CA2 and treated for
2 hours with concentrations of MZA ranging from 0.1 to 2 mm
resulted in a steeper binding curve compared to cells with
high levels of CA2, giving an apparent Kd similar, within the
error, to that measured in vitro (Supporting Information,
Figure S10a,b). Interestingly, treatment with 4 under the
same conditions resulted in an apparent Kd! 20-fold higher
than in vitro, thus suggesting that other molecules may
compete for binding 4 within the cell (Supporting Informa-
tion, Figure S10 c,d). Therefore, quantitative binding curves
obtained by NMR can provide meaningful information to
describe the kinetics and thermodynamics of intracellular
ligand binding.
Finally, to assess to which extent the “intracellular
protein-observed” approach can be generalized to other
intracellular targets, ligand binding was tested on intracellular
CA1. While CA1 reached lower expression levels than CA2,
histidine amide protons were still detected in the 1D 1H NMR
spectra, and free and bound species could be clearly separated
(Supporting Information, Figure S11). Therefore, the
approach should be applicable to other intracellular CA
isoforms, which contain conserved zinc-binding histidines,
and in principle to any other protein that gives rise to 1H
signals downfield of approximately 11 ppm[19] or in any
background-free spectral region. More in general, by recur-
ring to selective isotopic labelling strategies, such as amino
acid type-selective [13C]-methyl or [15N]-labelling, this
approach can be applied to any soluble intracellular protein,
provided that at least one signal is observable by in-cell NMR
and is sensitive to ligand binding.
Herein, we show that ligand screening can be performed
in human cells towards a specific protein by “intracellular
protein-observed” NMR. Since the first proof-of-principle in
human cells,[2] in-cell NMR application to protein-observed
ligand screening has been limited to bacteria.[28] The approach
shown here allows efficient in-depth drug screening in human
cells for assessing intracellular target-binding capabilities, and
also provides a way to characterize them in more quantitative
terms, without recurring to chemical tagging of the protein.[29]
The currently low throughput of the approach can be greatly
improved by increasing automation (for example, through the
use of a temperature-controlled NMR sample changer) and
by screening multiple ligands simultaneously (for example,
through matrix methods[28]). Importantly, this method does
not rely on enzymatic activity measurements. Therefore, it
provides a unique novel way to evaluate the effectiveness of
drugs also against non-enzymatic targets, each of them
otherwise requiring indirect cell-based assays to be estab-
lished, such as cell proliferation, invasion, and viability/
Figure 5. Time-dependent binding curves observed in cells expressing CA2 treated with either 27 mm AAZ (a) or 2 mm MZA (b) for increasing time
periods. Binding of AAZ was fitted with a time-dependent binding equilibrium; binding of MZA was fitted with a time-dependent diffusion in
deficiency of external ligand with respect to the protein (See the Experimental Methods section of the Supporting Information). Each dot
represents the area under a single peak in the imino region of the 1D 1H in-cell NMR spectra, normalized to the total spectral area.
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apoptosis assays. Ultimately, once framed within the modern
drug development pipeline, this method could allow the
assessment of the potency of a candidate drug, that is, the
amount of drug required to exert an effect of given intensity,
in a clinically relevant concentration range (0.1–100 mm). Such
predictive ability would allow the optimization of potency at
an earlier stage of the pipeline compared to cell- and animal-
based assays.
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1. Experimental Methods 
1.1. Gene cloning 
To generate the mammalian expression plasmids, the cDNAs encoding full-length human CA2 (amino 
acids 1–260, GenBank: NP_000058.1) and human CA1 (amino acids 1–261, 
GenBank: NP_001122303.1) were amplified by PCR and cloned into the pHLsec vector[1] between 
EcoRI and XhoI restriction enzyme sites (CA2) and between HindIII and XhoI restriction enzyme sites 
(CA1), following a previously reported cloning strategy.[2] These restriction sites were chosen in order 
to remove a N-terminal signal peptide and a C-terminal histidine tag present in the original vector, so 
that the expression vectors obtained with this strategy encode the native protein sequences. Specifically, 
CA2 was amplified using the following primers:  
Forward: 5’-CCGGAATTCGCCACCATGGCCCATCACTGGGGGTACGGC-3’;  
Reverse: 5’-CCGCTCGAGTTATTTGAAGGAAGCTTTGATTTGCCTGTTCTTC-3’;  
CA1 was amplified using the following primers:  
Forward: 5’-CCCAAGCTTGCCACCATGGCAAGTCCAGACTGGGGATATGATG-3’; 
Reverse: 5’-CCGCTCGAGTCAAAATGAAGCTCTCACTGTTCTGCCCTTC-3’.  
A Kozak sequence was inserted in both forward primers downstream of the EcoRI/HindIII site, while 
a stop codon was inserted in both reverse primers upstream of the XhoI site. The clones were verified 
by DNA sequencing.  
1.2. Human cell culture and transfection 
HEK293T (ATCC CRL-3216) cells were maintained in Dulbecco-modified Eagle medium (DMEM) 
high glucose (Gibco) supplemented with L-glutamine, antibiotics (penicillin and streptomycin) and 
10% fetal bovine serum (FBS, Gibco) in uncoated 75 cm2 plastic flasks and incubated at 37 °C, 5% 
CO2 in a humidified atmosphere. Cells were transiently transfected with the pHLsec plasmid containing 
the gene of CA2 or CA1 using polyethylenimine (PEI), with a DNA:PEI ratio of 1:2 (25 μg/flask DNA, 
50 μg/flask PEI). Lower expression levels of CA2 were obtained by transfecting cells with a mixture of 
5 µg CA2 DNA and 20 µg empty vector. DMEM medium was used for unlabelled in-cell NMR 
samples; [U-15N]-BioExpress6000 medium (Cambridge Isotope Laboratories) was used for uniform 15N 
in-cell NMR samples. Expression media were supplemented with 2% FBS, antibiotics and 10 µM 
ZnSO4.  
1.3. Protein quantification and intracellular distribution 
The expression level of CA2 was determined by Coomassie-stained SDS-PAGE. Densitometry analysis 











purified CA2 as a reference. CA2 expression at lower levels was assessed by SDS-PAGE of lysates 
from cells transfected with lower amounts of CA2 DNA (Figure S12a). CA1 level was estimated by 
comparison with CA2 (Figure S12b). The values reported in the main text reflect the protein 
concentrations calculated from cells lysed in 1 cell pellet-volume, therefore corresponding to the 
effective concentrations in the in-cell NMR samples (mean value ± s.d., n =3). Intracellular distribution 
was assessed by separating the insoluble fraction (containing the nuclei and other membranous 
fractions), the cytosolic and the mitochondrial fraction from cell extracts using a mitochondria isolation 
kit for cultured cells (Thermo Fisher Scientific), followed by analysis via SDS-PAGE of each fraction 
at serial dilutions. Following the separation, >90% of CA2 was recovered in the cytosolic fraction, 
whereas <5% was recovered in the insoluble fraction and <2% was recovered in the mitochondrial 
fraction (Figure S12d). 
1.4. Treatment with inhibitors  
HEK293T cells overexpressing CA2 or CA1 were treated with each inhibitor 48 hours post-transfection. 
Dose-dependent binding curves were obtained by treating different cell cultures with increasing 
amounts of each ligand for a fixed time (1 hour, unless specified differently in the main text). Time-
dependent binding curves were obtained by treating different cell cultures with a fixed amount of AAZ 
or MZA for increasing amounts of time. The cellular response to AAZ and MZA in terms of cell 
viability was assessed by trypan blue staining of cells overexpressing  CA2 and subsequently treated for 
1 hour with increasing concentrations of AAZ or MZA (0, 1, 10, 100 µM). Viability remained > 95% 
in all samples (Figure S12c).  
1.5. Stopped-flow measurements  
An Applied Photophysics stopped-flow instrument was used for assaying the CA2-catalysed CO2 
hydration activity.[3] CA2 was purchased from Sigma-Aldrich. Phenol red (at a concentration of 0.2 
mM) was used as indicator, working at the absorbance maximum of 557 nm, with 20 mM HEPES (pH 
7.5) as buffer, and 20 mM Na2SO4 (for maintaining constant the ionic strength), following the initial 
rates of the CA2-catalysed CO2 hydration reaction for a period of 10–100 s. The CO2 concentrations 
ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For 
each inhibitor at least six traces of the initial 5–10% of the reaction have been used for determining the 
initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the 
total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in distilled-deionized water 
and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions 
were preincubated together for 15 min at room temperature prior to assay, in order to allow for the 
formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares 
methods using PRISM 3 and the Cheng–Prusoff equation and represent the mean (± s.d.) from at least 










Cell lysates were prepared by freeze-thaw cycles in phosphate buffered saline (PBS), pH 7.4 followed 
by centrifugation for 1 hour at 16000 g, 4°C. The supernatant from each sample was collected. Total 
protein concentration in each sample was measured by BCA Protein Assay (Thermo Fisher), and the 
sample volumes were adjusted with PBS to equalize total protein concentration, and subsequently 
diluted 400-fold. Total CO2 hydration activity in the cell lysates was measured by stopped-flow using 
the same protocol described above.  
1.6. Expression and purification of recombinant CA2 
Recombinant CA2 for in vitro experiments was prepared following an existing protocol.[4] Briefly, a 1-
liter cell culture of E. Coli BL21(DE3) Codon Plus Ripl (Stratagene) transformed with a pCAM plasmid 
containing the CA2 gene was grown overnight at 37°C in LB, harvested and re-suspended in 1 liter of 
15N-labelled M9 medium. ZnSO4 was added in the culture to a final concentration of 500 µM. After 5 
h from induction with 1 mM IPTG at 37°C the cells were harvested and re-suspended in 20 mM Tris, 
pH 8 buffer for lysis. The cleared lysate was loaded onto a nickel chelating HisTrap (GE Healthcare) 5 
ml column. The protein was eluted with a linear gradient of 20 mM Tris pH 8, 500 mM imidazole. The 
fractions containing pure CA2 were collected. Finally, the protein was exchanged in NMR buffer (PBS 
pH 7.4, Gibco, supplemented with 10% D2O). The correct metalation of the protein was confirmed by 
chemical shift comparison against previously reported spectra. 
1.7. In vitro NMR experiments 
Samples of pure CA2 (170 µM in NMR buffer), both unlabelled and 15N-labelled, were placed in 5 mm 
NMR tubes and analyzed at 310 K at a 900 MHz Bruker Avance HD spectrometer equipped with a TCI 
CryoProbe. 1D 1H WATERGATE 3-9-19 (on the unlabelled protein) and 2D 1H-15N SOFAST-HMQC 
(on the 15N-labelled protein) spectra were acquired both in the absence of ligands and upon addition of 
1 equivalent of each ligand. The same CA2 samples were then titrated with up to 2 equivalents of each 
ligand and analyzed by NMR to exclude the presence of high-affinity secondary binding sites. For some 
ligands, poor solubility in aqueous buffer caused precipitate formation, without affecting protein 
solubility. In those circumstances, complete binding was obtained by adding step-wise 2-3 equivalents 
to the protein, spinning down after each addition to remove the precipitate.  
1.8. In-cell NMR experiments 
Samples for in-cell NMR were prepared following a reported protocol.[2] Briefly, cells overexpressing 
CA2/CA1 were detached with trypsin, suspended in DMEM + 10% FBS, washed once with PBS and 
re-suspended in one pellet volume of DMEM supplemented with 90 mM glucose, 70 mM HEPES and 
20% D2O. The cell suspension was transferred in a 3 mm Shigemi NMR tube, which was gently spun 
to sediment the cells. Cell viability before and after NMR experiments was assessed by trypan blue 
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2. Supplementary Figures 
 
Figure S1. (a) Overlay of 1H-15N NMR spectra of cells expressing CA2 (black) and in vitro CA2 (175 













Figure S2. Imino region of the 1D 1H NMR spectrum of CA2 in vitro (red) and in-cell (black). Signals 
for which the unambiguous assignment has been reported previously are labelled with the 
corresponding residue number and atom type.[7,8] Signals arising from unassigned protons are labelled 
with an asterisk. H94, H96 and H119 are the zinc-coordinating histidines in the active site of CA2.  
 
 
Figure S3. Total CO2 hydrase activity measured on lysates from HEK293T cells overexpressing CA2 
(CA2) and control cells with basal levels of CA2 (ctrl), either untreated or treated with 100 µM AAZ 













Figure S4. Overlay of 1H-15N NMR spectra of CA2 in vitro (175 µM) in the absence of ligands (black) 
and in the presence of 1 equivalent of (a) AAZ (red) or (b) MZA (magenta). The appearance of new 
sets of peaks in the presence of AAZ/MZA together with the complete disappearance of signals arising 




Figure S5. (a, b) in-cell 1H-15N CCSD between CA2 in the absence of ligands and bound to (a) AAZ; 









Figure S6. (a) Imino region of the 1D 1H NMR spectra of in vitro CA2 in the absence of ligands (black) 
and bound to 1 equivalent of AAZ (red) or MZA (magenta). (b) 1D 1H NMR spectra of in vitro CA2 in 
the absence of ligands (black) and upon addition of sub-stoichiometric amounts of AAZ (red) or MZA 
(magenta). Peaks arising from both free and bound CA2 are observed simultaneously. (c) Plot of the 1H 
chemical shifts observed in the same spectral region as in (a) and (b) in the in vitro NMR spectra of 
free CA2 (black), AAZ-bound CA2 (red) and MZA-bound CA2 (magenta), measured at pH 7.4, 



















Figure S7. Spectral deconvolution in the imino region of different in-cell NMR spectra expressing CA2 
at high (~150 µM) or low (~45 µM) levels. Both untreated cells (ctrl) and cells treated with 
concentrations of ligands that result in the incomplete binding are shown. The raw NMR data (black), 
single peak Pseudo-Voigt functions (red) and the overall sum (green) are shown. Calculated peak areas 
are indicated in red. In some instances, peaks with non-ideal shapes were fitted as the sum of two 
Pseudo-Voigt functions. Additional functions were used to correct fo r baseline distortions, the area of 





Figure S8. Imino region of the 1D 1H NMR spectra of cells expressing CA2 in the absence of ligands 
(black) and treated with ligands showing negligible binding to intracellular CA2: C18 (orange), 2, 5, 6, 

























Figure S9. Overlay of 1H-15N NMR spectra of CA2 in vitro (175 µM) in the absence of ligands (black) 
and in the presence of 1 equivalent of (a-h) ligands 1 to 8 (light blue) or (i) C18 (orange). (j) Imino 
region of the 1D 1H NMR spectra of CA2 in vitro in the absence of ligands (black) and bound to ligands 
1 to 8 (blue) or C18 (orange). Complete binding was not observed for the lowest-affinity ligand, 8, 













Figure S10. (a, c) Imino region of the 1D 1H NMR spectra of cells expressing CA2 at lower levels (~45 
µM in the NMR tube) in the absence of ligands (black) and treated for 2 hours with increasing 
concentrations of MZA (a, brown to yellow) or Molecule 4 (c, dark blue to cyan) at increasing 
concentrations. (b, d) Dose-dependent binding curves obtained from the NMR spectra shown in (a) and 
(c), respectively, fitted with a time-independent binding equation (see Experimental Methods). Binding 
of MZA reaches 50% at around 0.3 µM, giving an apparent Kd of 26 ± 12 nM (b), close to the Kd 
measured in vitro (14 ± 0.9 nM). Instead, binding of Molecule 4 requires a higher dose, giving an 
apparent Kd of 141 ± 27 nM (d), ~20-fold higher than in vitro (5.9 ± 0.4 nM), which suggests the 













Figure S11. Imino region of the 1D 1H NMR spectra of cells expressing CA1 (~50 µM in the NMR 
sample) in the absence of ligands (black) and in the presence of AAZ 10 µM and 100 µM (red), or MZA 







2.3 Intracellular binding/unbinding kinetics of approved drugs to carbonic 
anhydrase II observed by in-cell NMR 
 
In-cell NMR has been shown to be successful in characterization, at an atomic level, 
of interactions between a protein and its ligand within the cytoplasm of living cells. 
The approach that we have previously developed and applied to the study of CA II 
inhibitors, allowed us to identify and describe the behaviour of various ligands in 
physiological conditions. In fact, through the analysis of the chemical shift 
perturbations induced by the binding of different drugs, we were able to obtain 
pharmacologically relevant information regarding kinetic parameters and 
properties, such as cell permeability and affinity for an intracellular target. 
In this project, the same approach was applied to a set of approved CAII ligands, 
including some that were originally designed to inhibit different targets. Through 
in-cell NMR it was possible to determine dose- and time- dependent binding curves 
from which a range of unpredicted behaviours emerged, in some cases probably 
correlated to the off-target binding activity of these compounds. This, in addition 
of being of interest in outlining a preliminary profile of drugs, can be very 
interesting for testing and consequently accelerating the development of new 
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Abstract 
Candidate drugs rationally designed in vitro often fail due to low efficacy in vivo 
caused by low tissue availability or because of unwanted side effects. To overcome 
the limitations of in vitro rational drug design, the binding of candidate drugs to 
their target needs to be evaluated in the cellular context. Here, we applied in-cell 
NMR to investigate the binding of a set of approved drugs to the isoform II of 
carbonic anhydrase (CA) in living human cells. Some compounds were originally 
developed towards other targets, and were later found to inhibit CAs. We observed 
strikingly different dose- and time-dependent binding, wherein some drugs 
exhibited a more complex behavior than others. Specifically, some compounds 
were shown to gradually unbind from intracellular CA II, even in the presence of 
free compound in the external medium, therefore preventing the quantitative 
formation of a stable protein-ligand complex. Such observations could be correlated 
to the known off-target binding activity of these compounds, suggesting that this 
approach could provide information on the pharmacokinetic profiles of lead 







Classical rational drug design approaches aim at maximizing the activity towards a 
specific target in vitro. However, drug efficacy in vivo can be affected by many 
factors, such as low tissue availability, binding to off-target biomolecules, or 
unwanted side effects. Therefore, ideally, the binding to an intracellular target 
should not only be evaluated in vitro, in isolated conditions, but also directly in the 
cellular context, where poor cell penetrance or the occurrence of off-target binding 
can negatively affect the activity of potential drugs towards their main target. Cell-
based activity assays provide an indirect measure of the effect of a drug, but may 
not easily discriminate the molecular origin of the cellular response. Ideally, the 
interaction of a potential drug with the intracellular target should be monitored 
directly at atomic resolution. 
Among the existing atomic-resolution structural techniques, Nuclear Magnetic 
Resonance (NMR) spectroscopy stands out for its ability to investigate protein-
ligand interactions in solution at physiological temperatures.1–3 Furthermore, in-cell 
NMR approaches have been developed that allow the atomic-level characterization 
of proteins and nucleic acids directly in living cells.4–8 In the context of drug 
development, in-cell NMR has revealed to be a promising tool, as it can characterize 
interactions between small molecules and an intracellular target.9–12 Recently, we 
have employed in-cell NMR to investigate the interaction between multiple ligands 
and the second isoform of human carbonic anhydrase (CA, EC 4.2.1.1), CA II, in 
living human cells.13 This approach relies on the perturbation of the protein 
chemical shifts induced by ligand binding and allows an atomic-level description 
of the ligand binding site and, simultaneously, the measurement of intracellular 
dose- and time-dependent binding curves. From the latter data, important 
physicochemical properties of the ligands can be estimated, such as membrane 
permeability and apparent binding affinity, which are critical to assess the potency 
of the drugs towards the specific target.13 
Carbonic anhydrases (CAs) are ubiquitous metalloenzymes that catalyze the 
conversion of CO2 and H2O to HCO3
− and H+.14 In humans, 15 isoforms have been 
identified, all belonging to the α-class, which contain a catalytic zinc ion in the 
active site coordinated by three conserved histidine residues and a water 
molecule/hydroxide anion in a distorted tetrahedral geometry.15 Although they have 
a high structural homology, the human isoforms differ in catalytic activity, 
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structural properties of the binding cavity, subcellular localization and response to 
exogenous molecules.14–16 The CO2 hydration reaction catalyzed by CAs is 
involved in many physiological processes, such as transport of CO2 between tissues 
and lungs during respiration, pH homeostasis, electrolyte transport in various 
tissues, and several biosynthetic pathways.14 Importantly, CA isoforms have been 
implicated in several pathological states, such as epilepsy, glaucoma, 
cardiovascular diseases and cancer.17 Given the relevance of CAs as 
pharmacological targets, CA inhibitors have been developed over the course of 
several decades, some of which are currently administered in the treatment of 
glaucoma and epilepsy, and as diuretics.14 Current efforts are now focused on the 
development of CA inhibitors with higher isoform selectivity, which would allow 
the selective inhibition of a single isoform, thereby reducing the required dose for 
treatment and the insurgence of adverse effects.16,17 Indeed, a selective inhibitor of 
CA IX is currently in clinical development as antitumor agent.18,19  
Here, we applied the above in-cell NMR approach to screen in human cells the 
binding to CA II of a set of approved drugs that are known to inhibit human CAs. 
We focused on a selection of sulfonamide compounds representative of different 
categories of drugs, including anti-inflammatory drugs originally designed to 
inhibit non-CA targets, diuretics and anticonvulsants which exert their function 
through inhibition of multiple targets, including CAs, and an anticancer drug 
currently under clinical trials that was specifically designed to inhibit the tumor-
associated isoform CA IX. While the chemical shift perturbation confirmed that all 
the ligands bound CA II in the active site of the protein, in accordance to the in vitro 
characterization, we observed strikingly different behaviors from the dose- and 
time-dependent binding data for each ligand. Specifically, while the binding mode 
of some ligands could be explained by diffusion-limited, strong binding kinetics, 
other ligands diverged from such simplistic model and exhibited a more complex 








RESULTS AND DISCUSSION 
 
Properties of the investigated drugs 
The structures of the investigated drugs and their properties are summarized in 
Chart 1 and Table 1. Celecoxib 1 and valdecoxib 2 are first- and second-generation 
COX-2-selective inhibitors, respectively, employed as nonsteroidal anti-
inflammatory drugs (valdecoxib was withdrawn from clinical use); indapamide 3 
(racemic mixture), furosemide 4 and hydrochlorothiazide 5 are high-ceiling 
diuretics, which reduce sodium reabsorption in the kidneys by binding to the 
electroneutral sodium-chloride cotransporter and are employed treat hypertension, 
edema and congestive heart failure; zonisamide 6 is a widely used antiepileptic drug 
which binds to voltage-sensitive sodium and calcium channels; ethoxzolamide 7 is 
a diuretic, also employed to treat glaucoma, that inhibits CAs in proximal renal 
tubules; SLC-0111 8 is a recently developed CA IX inhibitor currently undergoing 
phase II-b clinical trial as an anticancer/antimetastatic agent; methazolamide 9 is a 
potent CA inhibitor employed in the treatment of glaucoma. Compounds 1-6 were 
not originally designed as CA inhibitors, but have been shown later to inhibit 
several pharmacologically relevant CA isoforms with nanomolar affinity.14,20–25 
Conversely, compounds 7 and 8 were designed purposefully to inhibit CA activity. 
9 is a well-characterized compound, which was previously observed to bind 
quantitatively CA II in human cells by NMR13 and was included as a reference 
compound in the current study. 
 
Drug binding monitored by 1H NMR 
Drug binding to the intracellular protein was investigated by in-cell NMR by 
analyzing HEK293T cells transiently overexpressing CA II and subsequently 
treated with each compound at different doses and incubation times. In our 
experimental conditions, CA II reaches an average concentration of 150 ± 20 M 
in ~150 L of cell pellet (see Methods), as previously reported.13 Amino 1H signals 
arising from three histidine side chains located in the CA II active site, as well as 
1H from other aromatic side chains, were clearly identified in the region of the 1D 
1H NMR spectrum between 11 and 16 ppm (Figure 1). This spectral region is well-
resolved and free from cellular background signals, therefore it can be analyzed 
without recurring to 15N isotopic labeling, that is often necessary to reduce spectral 
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overlap and avoid interference from non-NH background signals. Ligand binding 
induces changes in the chemical environment of the active site, giving rise to a new 
set of signals arising from the bound protein (Figure 2). In aqueous buffer, all the 
compounds quantitatively bound CA II when added in stoichiometric amount, 
giving rise to distinct patterns of clearly resolved signals (Figure 2a).  
 
Fixed-dose drug screening  
The intracellular binding of each compound was initially assessed by treating CA 
II-expressing cells with a 100 M dose of each compound in 20 mL of external 
medium, therefore in ~100:1 molar ratio with respect to the protein (2×10-6 mol of 
compound vs. ~2×10-8 mol of CA II), followed by 1-hour incubation, removal of 
the external solution, cell detachment and NMR analysis. The bound fraction for 
each compound was obtained as a time average from a 30 minutes-long in-cell 
NMR spectrum. Binding to CA II was observed for all compounds, although at 
varying degrees (Figure 2b). In cells, the chemical shifts of the bound state matched 
those observed in vitro, indicating that the binding mode of the compounds was 
essentially unchanged in the cellular setting. Additional line broadening, caused by 
faster transverse relaxation and magnetic inhomogeneity of the cell sample, resulted 
in an increased overlap between signals, which was overcome by signal 
deconvolution (Figure S2, see Methods). The fractions of free and bound 
intracellular protein could then be quantified by comparing the relative signal 
intensities of the two species in the in-cell 1H NMR spectra (Figure S2 and Figure 
3). The large differences observed in the bound protein fractions at such a high dose 
treatment could not be explained with the different KIs reported in vitro (Table 1) 
and suggested that the incomplete binding could be the consequence of poor drug 
permeability, as previously observed for other CA inhibitors.13 Notably, the two 
enantiomers of 3 bound CA II in equal amounts in vitro, resulting in two distinct 
sets of signals with similar intensities (Figure 2a). A similar pattern was also 
observed in cells, suggesting that the two enantiomers bound intracellular CA II 
with similar affinity, however the broader spectral lines and the presence of signals 





Dose- and time-dependent drug binding  
The dose- and time-dependency of binding was assessed by analyzing CA II-
expressing cells treated with increasing doses of each compound (ranging from 10 
to 100 M in the external medium) and incubated for increasing times (ranging 
from 30 minutes to 2 hours). The bound fraction in each condition was obtained 
from a 30 minutes-long NMR experiment as above (Figure 4). Compounds 7-9, 
which bound CA II completely at 100 M for 1 hour, gave essentially the same 
results both with shorter incubation time (30 minutes), and with a much lower dose 
(10 M, still a ~10 fold molar excess with respect to the total CA II), whereas 
compounds 1-6, which did not bind CA II completely at 100 M, showed different 
dose and time dependencies. Specifically, the fraction of CA II bound to 4 and 5 
increased linearly as a function of time, consistent with binding kinetics limited by 
the plasma membrane permeability, irrespective of the binding affinity for CA II. 
Instead, CA II binding of compounds 1-3 and 6 did not show any dose or time 
dependency in the 50-100 M range and reached a plateau at ~70-80% (1), ~50-
60% (2), ~80-90% (3) and ~35-40% (6), indicating that the observed results in that 
dose range were not dependent on membrane permeability. For compounds 1 and 
8, treatment at 10 M dose resulted in a decrease of CA II bound fraction and 
allowed estimating the rates of permeability through the plasma membrane, in 
addition to those obtained from the time dependency of 4 and 5 at high dose (Table 
2, see Methods), whereas no significant decrease was observed at 10 M dose for 
compounds 2, 3, 6, 7, 9, indicating a permeability KP∙A > 6∙10
-7 dm3 s-1.  
 
Unbinding kinetics by time-resolved in-cell NMR  
To further investigate the origin of the plateau effect observed in the 50-100 M 
dose range, cells treated with 100 M for 1 hour (i.e. the same conditions for which 
time-averaged data was reported, see Figure 3) were analyzed as a function of time 
by performing a series of short in-cell NMR experiments over a total experimental 
time of 1 hour (Figure 5, red and magenta curves). Interestingly, the binding of 
compounds 1-3 and 6 to intracellular CA II exhibited a marked time dependence, 
decreasing respectively from ~100% to ~66% (1), from ~90% to ~45% (2) from 
~100% to ~75% (3) and from ~50% to ~30% (6) after 1 hour (values at time 0 were 
extrapolated), whereas compounds 4 and 5 showed a less pronounced time 
dependence (Figure 5). These values are fully consistent with the measurements 
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averaged over 30 minutes, and indicate that these compounds are gradually released 
during the acquisition of the NMR spectra, thereby explaining the incomplete 
binding observed in the averaged data (Figure 3). In order to assess whether the 
same effect could occur in the cell culture, cells treated for 1 hour with compounds 
1-3 and 6 in the CO2 incubator were washed to remove the external ligand and 
further incubated in fresh medium without ligands. Quantitative NMR analysis of 
lysates from cells collected at increasing times showed that a similar unbinding 
behavior also occurred in the cell culture, although to a lower extent (Figure S3). 
The unbinding from CA II was also investigated in samples, initially treated with 
100 M compound for 1 hour, where the compound was re-introduced in the 
external solution of the cells during the NMR measurement (Figure 5, black and 
blue curves). Notably, while the unbinding of 1, 3, 4 and 5 was only partially 
mitigated in those conditions, compounds 2 and 6 showed a marked increase of 
bound protein at time 0. Therefore, the observed unbinding from CA II could be 
partially explained with the diffusion of ligand molecules from the cytosol back to 
the external solution (Figure S3). However, the observation of unbinding even in 
the presence of external ligand (Figure 5) indicates that this phenomenon is not 
driven solely by passive diffusion. 
 
Drug classification based on binding behavior 
The above results show that the interplay between active compound, intracellular 
target, plasma membrane and cellular milieu can generate complex binding 
behaviors that are not easily described with a simple diffusion model. Nevertheless, 
the binding data obtained by in-cell NMR allowed a coarse-grained classification 
of the screened molecules. Based on the diffusion properties of the compounds 
(Table 2) and on the presence/absence of unbinding kinetics (Figure 5), the 
following classes are obtained: I) fast-diffusing, stable binding (7, 8, 9); II) slow-
diffusing, stable binding (4, 5); III) fast-diffusing, unstable binding (1, 2, 3, 6). 
Slow-diffusing, unstable binding compounds were not observed, although it is 
possible that the slow diffusion of 4 and 5 masks the effects of binding instability. 
Strikingly, all class-I compounds have a mechanism of action that involves strong 
CA inhibition, or were even rationally designed for selective CA inhibition (8), 
whereas class-II and III compounds were not primarily intended for CA inhibition 
and have known activity towards other targets. This correlation suggests that the 
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intracellular screening performed here could be used as a predictive tool to assess 
the specificity of a drug towards the desired intracellular target.  
Binding of class I and II compounds follow a simple diffusion-limited binding 
behavior, where at low doses / short times the fraction of bound CA II depends 
linearly on the permeability of the compounds through the plasma membrane, while 
at high doses / long times CA II is fully bound to the compounds. In the dose and 
time ranges investigated, complete binding was only observed for class I. In such 
regime, ligand binding is likely not affected by changes in the intracellular binding 
affinity, due to the intracellular concentration of CA II being in the ~100s M range 
while the KIs are in the nM-M range.  
Class-III compounds behave essentially like class-I during the cell incubation step, 
quickly diffusing through the plasma membrane and binding quantitatively to CA 
II (Figure 4 and Table 2), but are then partially released once the cells are detached 
for NMR analysis (Figure 5). Notably, while some release was observed prior to 
cell detachment after the compounds were removed from the cell growth medium 
(Figure S3), it also occurred when the ligand molecules in excess were kept in the 
external solution in the NMR tube (Figure 5). In the latter case, a delay in the onset 
of the unbinding was introduced together with an increase in the final fraction of 
bound CA II, while the slope of the curves was not affected. Although several 
scenarios are possible, such behavior may be partially explained by a model in 
which an additional species competes against CA II for ligand binding. However, 
this competitor must be introduced in the system after cells are detached for NMR 
analysis, otherwise it would have already been saturated with ligand molecules 
during the incubation step. It is possible that a change in membrane protein 
composition induced by trypsinization affects the turnover and the cellular 
localization of membrane proteins, including the known targets of class-III 
compounds, namely the membrane-bound COX-2 (1, 2), the integral membrane 
proteins sodium-chloride cotransporter (3) and voltage-sensitive channels (6). This 
change would cause the emergence of a pool of competing binding sites that 
subtracts the ligands from CA II, with a kinetic behavior that can be modulated by 
the presence of additional ligand molecules in the external solution. However, these 
results only allow for speculation, as they report specifically on the free and bound 
fractions of CA II, with no information on the binding of the compounds to other 
intracellular targets. Furthermore, CA II has to be overexpressed to allow for NMR 
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detection, making it in excess with respect to the competing targets, thus further 
complicating the interpretation of the results.  
 
Conclusions 
The above findings show that the application of in-cell NMR to investigate drug 
binding to an intracellular pharmacological target could have a relevant role in the 
drug discovery process. Indeed, this approach could provide early-stage 
information on the pharmacokinetic profiles of lead candidates and allow 
preclinical investigations already at the drug-design and lead identification stages. 
Furthermore, small-scale screenings such as the one reported here could predict the 
specificity of a drug towards the desired target or, as in the case for class-III 
compounds described above, warn against possible multi-target behavior.  
Recently, in addition to the classical drug development routes, there has been a 
growing interest in polypharmacological approaches, which aim at exploiting the 
off-target activities of drugs in combination with the activity towards their original 
targets for the treatment of complex disease states.26 Due to their involvement in 
different pathological states, human CA isoforms are ideal targets for multi-target 
drugs.17 Indeed, drugs such as those investigated here could be employed in novel 
therapeutic strategies in which CA inhibitors have been shown to be effective, such 
as against obesity, arthritis, cerebral ischemia and neuropathic pain,27 by exploiting 
their multi-targeting effect.  
Here, intracellular ligand screening by NMR revealed an unpredicted behavior of 
some of these hybrid drugs, possibly as a consequence of their activity towards 
multiple targets. In this context, the in-cell NMR approach could have a marked 
relevance when designing and characterizing multi-target compounds, driving 
further optimization in the search of a balanced multi-targeting efficacy and 
accelerating the development of next-generation polypharmacological drugs, also 
beyond the field of CAs. From a methodological standpoint, further advancements 
will be needed to allow observing the binding of a compound to multiple 
intracellular targets simultaneously, without requiring their overexpression. In this 
respect, NMR bioreactors have proven valuable tools to increase both sensitivity 
and time resolution of the methodology.28,29 In parallel, 19F is being increasingly 
exploited as a sensitive and background-free probe for cellular NMR studies,11,30,31 
hence a ligand-observe in-cell NMR approach could be envisaged that employs 19F-
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labeled compounds to obtain a more complete picture of their fate inside the cells 




Human cell cultures 
HEK293T cells (ATCC CRL-3216) were maintained in Dulbecco-modified Eagle 
medium (DMEM) high glucose (Gibco) supplemented with L-glutamine, 
antibiotics (penicillin and streptomycin) and 10% fetal bovine serum (FBS, Gibco) 
in uncoated 75 cm2 plastic flasks and incubated at 37 °C, 5% CO2 in a humidified 
atmosphere. HEK293T cells were transiently transfected, following a previously 
reported protocol,32 with the pHLsec33 plasmid containing the full-length human 
CA II gene (amino acids 1–260, GenBank: NP_000058.1)13 using branched 
polyethylenimine (PEI). A DNA:PEI ratio of 1:2 (25 μg/flask DNA, 50 μg/flask 
PEI) was used. Protein expression was carried out in DMEM medium supplemented 
with 2% FBS, antibiotics and 10 M ZnSO4. CA II concentration was calculated as 
previously reported13 from cells lysed in 1 cell pellet volume, corresponding to the 
effective concentrations in the in-cell NMR samples (mean value ± s.d., n = 3), and 
measured by SDS-PAGE by comparing serial dilutions with a sample of purified 
CA II. Compounds 1-9 were purchased from Sigma-Aldrich or TCI Europe and are 
≥ 97% HPLC pure. Cells overexpressing CA II were treated with the compounds 
48 hours post-transfection, by dissolving a concentrated DMSO stock solution of 
each compound (80 mM) directly in 20 mL of growth medium in the cell culture 
flask. Experiments were performed by treating cells with varying amounts of each 
compound and incubated for varying amounts of time as specified in the Results 
section. Control cell samples were incubated for 1 hour with pure DMSO (0.125% 
final concentration). Cell viability remained > 95%, as assessed by trypan blue 
exclusion assay, and was not affected by treatment with any the compounds in the 
dose and time ranges employed in the study (data not shown). 
 
In-cell NMR sample preparation 
Samples for in-cell NMR were prepared as previously reported.32,34 Transfected 
cells were detached with trypsin, suspended in DMEM + 10% FBS, washed once 
with PBS and re-suspended in one pellet volume of NMR medium, consisting of 
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DMEM supplemented with 90 mM glucose, 70 mM HEPES and 20% D2O. The 
cell suspension was transferred in a 3 mm Shigemi NMR tube, which was gently 
spun to sediment the cells. For the unbinding experiments in the presence of 
compound in the external solution, cells were prepared following the above 
protocol and resuspended in one pellet volume NMR medium supplemented with 
100 M of compound. Cell viability before and after NMR experiments was 
assessed by trypan blue exclusion assay. After the NMR experiments, the cells were 
collected and the supernatant was checked for protein leakage by NMR.  
 
Cell lysate sample preparation 
Cultures of HEK293T cells overexpressing CA II were incubated with 100 M of 
compound for 1 hour. A control cell culture was immediately detached with trypsin, 
pelleted and frozen at -20°C. The remaining cell cultures were washed once with 
PBS and resuspended in fresh DMEM supplemented with 2% FBS, antibiotics and 
10 M of ZnSO4, in the absence of compound. Cells were incubated for varying 
amounts of time (30 min, 1 and 2 hours) and subsequently collected and frozen at -
20°C. Cell lysates were prepared by freeze-thaw cycles in PBS buffer followed by 
centrifugation to remove the insoluble fraction. The supernatants were 
supplemented with 10% D2O, placed in a standard 3-mm NMR tube and analyzed 
by NMR.  
 
In-cell NMR spectra acquisition and analysis 
In-cell NMR spectra were collected at 310 K either at a 900 MHz Bruker Avance 
NEO or at a 950 MHz Bruker Avance III spectrometer, both equipped with a 5 mm 
TCI CryoProbe. 1D 1H NMR spectra were recorded with a WATERGATE 
experiment using a 3-9-19 binomial pulse train for water suppression (Bruker 
p3919gp pulse program).35 Time-averaged NMR spectra were recorded with 1024 
scans (total experimental time of 28 minutes). Time-resolved NMR data were 
collected by recording 16 1H NMR spectra, with the same parameters as above, 
with 128 scans each (total experimental time of 57 minutes). The spectra were 
processed with Bruker Topspin 4.0 by applying zero filling and exponential line 
broadening (LB = 20 Hz). To retrieve the area under each signal, the region between 
11 and 16 ppm of each spectrum was fitted with Fityk36 using a sum of N+1 pseudo-
Voigt functions (gaussian weight fixed at 0.15), where N equals the number of 
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discernible signals in the region and the additional function accounted for the 
baseline distortion. Peak areas for each spectrum were normalized by the sum of 
the N areas. Relative fractions of free and bound CA II were obtained by 
Multivariate Curve Resolution – Alternate Least Square (MCR-ALS) analysis,37 
using the MCR-ALS 2.0 GUI38 in MATLAB according to a previously reported 
protocol.29 The contribution of each CA II species to the signal intensities was 
retrieved from 2D arrays (one array per compound) containing the peak areas (rows 
= experiments, columns = peaks). Error bars for each fitting were obtained as 
follows: err = 2 × [lack of fit(%)] ⁄ 100. 
Non-linear curve fitting of the binding data was performed in OriginPro 8 with the 











where [Pt] is the total intracellular protein concentration, [LP] is the bound protein 
concentration, Kd is the dissociation constant and C is the apparent fraction of 
ligand-bound CA II at plateau, which is < 1 in the presence of unbinding effects. 
[Lt.in](t) is the total intracellular ligand concentration defined as: 






where Lt = Lo + Li + LP are the total moles of ligand (Lo and Li are the extracellular 
and intracellular ligand, respectively), Vt is the total external volume, Kp is the 
permeability coefficient and A is the total area of the membrane. 
 
Expression and purification of CA2 
Recombinant CA II was prepared following an existing protocol.39 Briefly, a 1 l 
cell culture of E. Coli BL21(DE3) Codon Plus Ripl (Stratagene) was transformed 
with a pCAM plasmid containing the CA II gene, grown overnight at 37 °C in LB, 
harvested and re-suspended in 1 l M9 medium. ZnSO4 was added in the culture to 
a final concentration of 500 M. After 5 h from induction with 1 mM isopropyl β-
d-1-thiogalactopyranoside (IPTG) at 37 °C, the cells were harvested and re-
suspended in 20 mM Tris buffer, pH 8 for lysis. The cleared lysate was loaded onto 
a nickel chelating HisTrap (GE Healthcare) 5 ml column. The protein was eluted 
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with a linear gradient of 20 mM Tris pH 8, 500 mM imidazole. Fractions containing 
pure CA II were collected. Finally, the protein was exchanged in NMR buffer 
(HEPES 20 mM pH 7.5, supplemented with 10% D2O). The correct metalation of 
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Figure 1. Top: imino region of the 1D 1H NMR spectrum of CA II in human cells 
(red) overlaid to the spectrum of the cellular background obtained from cells 
transfected with empty vector (blue). Bottom: 1D 1H NMR spectrum of CA II in 
aqueous buffer (black). Residues for which the unambiguous assignment has been 
reported previously are labeled with the corresponding residue number and atom 
type.40,41 H94, H96 and H119 coordinate the zinc ion in the active site. Signals 





Figure 2. Imino region of the 1H NMR spectra of CA II (a) in aqueous buffer and 
(b) in human cells in the absence (red) and in the presence (black) of the compounds 
investigated in this study. In vitro and in-cell NMR spectra were recorded for 15 
and 30 minutes, respectively. In (a), the signals which arise from CA II bound to 
the two enantiomers of 3 are labeled with an asterisk. In (b), signals arising from 




Figure 3. Bound fraction of intracellular CA II after incubation with 100 M of 
each compound for 1 hour, measured as a time average over 30 minutes. Error bars 
were obtained from the MCR-ALS global fitting of each dose/time-dependence 





Figure 4. Dose and time dependence of the binding of each compound to 
intracellular CA II. Each bar plot shows the fraction of CA II bound to a given 
compound after incubation at different concentrations and incubation times, 
measured as a time average over 30 minutes. Error bars were obtained from the 





Figure 5. Time-dependence of the intracellular fractions of free (black, red) and 
bound (blue, magenta) CA II in the NMR spectrometer measured in the absence 
(red and magenta) and in the presence (black and blue) of 100 M of external ligand. 
Error bars were obtained from the MCR-ALS global fitting as follows: err = 2 × 










Table 2. Permeability coefficient and fraction of bound CA II at plateau calculated 
for each compound from the non-linear fitting of the dose- and time-dependent 
binding data.  
 
n KP∙A (dm3 s-1) 
Bound CA II at 
plateau  
1 2.8 ± 0.7 ∙ 10-7 78 ± 3 % 
2 > 6 ∙ 10-7 53 ± 2 % 
3 > 6 ∙ 10-7 86 ± 5 % 
4 1.6 ± 0.4 ∙ 10-8 100 % 
5 1.8 ± 0.2 ∙ 10-8 100 % 
6 > 6 ∙ 10-7 36 ± 5 % 
7 > 6 ∙ 10-7 100 % 
8 5.4 ± 0.3 ∙ 10-7 100 % 
9 > 6 ∙ 10-7 a 100 % 
 
apreviously measured KP∙A = 1.2 ∙ 10
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Figure S1 (cont.) 
 
Figure S1. Spectral deconvolution in the imino region of 1D 1H NMR spectra of 
cells expressing CA II both untreated (ctrl) and treated for 1 hour with 100 µM of 
each compound (1-9). The raw NMR data (black), the Pseudo-Voigt functions of 
each peak (red) and the overall sum (green) are shown. Peak areas are indicated in 
red. In some instances, peaks with non-ideal shapes were fitted as the sum of two 
Pseudo-Voigt functions (e.g. 6). An additional Pseudo-Voigt function was used to 






Figure S2. Time-dependence of free (black) and bound (red) CA II in cell lysates 
from cells treated for 1 hour with 100 µM of compounds 1-3 and 6 and subsequently 
washed and incubated in the absence of compound for different times. Error bars 
were obtained from the MCR-ALS global fitting as follows: err = 2 × [lack of 


























During my doctoral work, I have been working on three different research projects 
focused on studying protein-protein and protein-ligand interactions via NMR. 
The first concerned the structural characterization of the third domain of CCS, both 
in the homodimer and in the heterodimer with SOD1. To overcome the signal 
overlapping problems caused by the large size of the protein, and to make the 
spectrum more easily interpretable, it was decided to apply a segmental labelling 
technique known as protein trans splicing. To achieve this goal, different 
methodologies were applied, among which, a new constructs design turned out to 
be the most promising approach. In fact, the new design allowed us to overcome 
the solubility problems encountered with previous approaches and to obtain a 
higher yield in the trans-splicing reaction. Despite these improvements, the 
difficulties in purification did not allow us yet to obtain a sample of FL-CCS 
sufficiently pure for the NMR analysis. However, new purification strategies are 
possible and some parameters can be optimized to achieve better purity levels.  
In parallel, a novel methodology for ligand screening directly in living human cells 
was developed. In-cell NMR was here applied to observe and characterize the 
binding and the behavior of a selected set of drugs towards an intracellular protein, 
i.e. CA II. From fast and cost-effective 1H NMR experiments, we were able to 
obtain meaningful dose- and time- dependent binding curves from which it was 
possible to extract thermodynamic and kinetic parameters closely related to the cell 
permeability, and also to the affinity and selectivity of a drug for its target. 
Furthermore, the integration of this method with the classical drug design pipeline 
can provide significant information about the potency of a drug and as consequence 
on the required dose to exert a certain effect. This will allow to select the most 
promising drug candidates already at the earliest stages of the entire development 
process thus increasing the chances of success.  
Finally, in the last research project, the previously developed method was applied 
to investigate the binding properties of a broader and most various selection of 
approved drugs towards intracellular CA II. The tested compounds included some 
drugs which do not have CAII as first target. Through in-cell NMR analysis, ligands 
were classified according to their binding behavior and three different classes 
emerged: I) fast-diffusing, stable binding; II) slow-diffusing, stable binding; III) 
fast-diffusing, unstable binding. The first two include ligands that followed a classic 
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diffusion-limited binding pattern, while the class three compounds showed a more 
complex behavior probably due to their off-target binding properties. Indeed, after 
an initial fast diffusion through the cell membrane and binding to CAII, they were 
progressively released. Although it is difficult to hypothesize the cause of this 
behavior, the most plausible explanation could be a competition binding effect 
occurring after the cells were collected, and probably induced by trypsinization.  
Intracellular ligand screening by NMR revealed to be a powerful approach to 
accelerate the drug design process. In fact, through its application, it is not only 
possible to predict the specificity of a drug for its target but also to identify its 
possible multi-target activity. In this regard, the in-cell NMR approach may be 
particularly useful in the polypharmacology field in which the multi-target 





































4. MATERIALS AND METHODS 
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4.1 Cloning and ligation 
CCS D1D2, CCS D3, Intein N and Intein C sequences were amplified separately 
trough polymerases chain reaction (PCR) using the following primers: 
 
 
BamHI Nde: restriction sites  
6H: histidine tail  
*mutation: - CCS_D3_Arg_for → from the original Arg (CGC) to Cys (TGC) 
In red: stop codons 
 
The PCRs were conducted with the following reagent volumes and amplification 
protocol. 
Reagents: Amplification protocol: 
 
H2O: 35,5 l  4 min at 95°C 
PCR buffer: 5 l        30s at 95°C 
dNTPs: 1,5 l      45s at 60°C 
Primer forward (~100 ng): 3 l      30s at 72°C (30X) 
Primer reverse (~100 ng): 3 l      5 min at 72°C 
DNA (~10 ng): 1 l       Then 4°C 
Polymerases: 1 l  
Total volume (single Eppendorf tube): 50 l 
 
The amplified fragments were ligated with T4 ligases (Thermo Fisher Scientific) at 
25°C for 75’ and then 65°C for 10’ to deactivate the enzyme with the following 
reagent volumes: 
Reagents 
2 μl PEG  
2 μl Buffer 
1 μl Ligase T4  
100 ng/ μl fragment 1 (different ratio was tried) 
100 ng/ μl fragment 2 (different ratio was tried) 
H2O until 20 μl of total volume 








D1D2_231_for T7 promoter primer 
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The ligation product was then amplified again and cloned into a PET11a (fig. 18) 
plasmid between Nde and BamHI restriction site. 
 
 
            Figure 18. pET-11a expression vector map 
 
After every phase an agarose gel electrophoresis was performed to check the correct 
happening of the amplification/ligation procedures.  
 
4.2 Agarose gel electrophoresis  
 
1.2 % agarose gel was prepared using 1 x TAE buffer (Tris base 40 mM, acetic acid 
20 mM and EDTA 1 mM). Once the gel was solidified the samples previously 
treated with Sybr green dye were loaded. 6 l of low/high range marker (Thermo 
Fisher Scientific) were used. Run was performed for 40’ at 90 V.  
 
4.3 Recombinant protein productions 
 
4.3.1 CCS D1D2-IntN construct 
E. Coli C41 DE3 strain was transformed with pET11a plasmid encoding D1D2-
IntN synthetized construct and then incubated at 37°C ON on LB agar plate with 
ampicillin antibiotic. The day after a 1-liter LB medium flask culture was prepared 
starting from a selected colony and bacterial cells were incubated at 37°C 180 rpm. 
Protein expression was induced at OD600 = 0.6 with 0.5 mM of IPTG and growth 
temperature was lowered at 30°C. After 4h from the induction cells were harvested 
and centrifuged at 4500 rpm for 20’. The pellet was resuspended in Tris 20 mM, 
NaCl 0.5 M, Imidazole 0.5 mM, TCEP 0.5 mM pH 8 purification buffer and cell 
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lysis was performed through a series of sonication cycles. The soluble fraction was 
then extracted by centrifugation at 8000 rpm for 90’ and loaded onto a previously 
equilibrated His-trap affinity Ni-column. The elution was performed using Tris 20 
mM, NaCl 0.5 M, Imidazole 0.5 M, TCEP 0.5 mM pH 8 buffer. The final 
purification step consisted in a size-exclusion chromatography using a Superdex75 
16/60 75 pg column in Tris 20 mM, NaCl 0.5 M TCEP 0.5 mM pH 8 buffer.  
The purification under denaturing conditions was realized following the previously 
reported protocol at 8 M of urea concentration.  
 
4.3.2 CCS IntC-D3 construct 
E. Coli BL21 Gold strain was transformed with pET11a plasmid encoding IntC-D3 
synthetized construct and then incubated at 37°C ON on LB agar plate with 
ampicillin antibiotic. The day after a 1-liter M9 unlabelled medium flask culture 
was prepared starting from a selected colony and bacterial cells were incubated at 
37°C 180 rpm. Protein expression was induced at OD600 = 0.6 with 0.5 mM of IPTG 
and growth temperature was lowered at 20°C ON. The purification both in normal 
and under denaturing conditions was performed using the previously reported 
protocol. 
 
4.3.3 Strep-MBP-TEV-CCS_D1D1-IntN   
E. Coli BL21 Gold strain was transformed with plasmids encoding Strep-MBP-
TEV-CCS_D1D1-IntN new synthetized construct and then incubated at 37°C ON 
on LB agar plate with kanamycin antibiotic. The day after a 1-liter LB medium 
flask culture was prepared starting from a selected colony and bacterial cells were 
incubated at 37°C 180 rpm. Protein expression was induced at OD600 = 0.6 with 1 
mM of IPTG and growth temperature was lowered at 30°C ON. Bacterial cells were 
harvested and centrifuged at 4500 rpm for 20’ and then the pellet was resuspended 
in Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer. 
 
4.3.4 MBP-IntC-CCS_D3_SGV 
E. Coli BL21 Gold strain was transformed with plasmids encoding MBP-IntC-
CCS_D3_SGV new synthetized construct and then incubated at 37°C ON on LB 
agar plate with ampicillin antibiotic. The day after a 1-liter LB medium flask culture 
was prepared starting from a selected colony and bacterial cells were incubated at 
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37°C 180 rpm. Protein expression was induced at OD600 = 0.6 with 1 mM of IPTG 
and growth temperature was lowered at 30°C. After 5h from the induction cells 
were harvested and centrifuged at 4500 rpm for 20’. The pellet was then 
resuspended in Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer. 
 
4.3.5 D1D2-IntN and IntC-D3 constructs refolding 
The two constructs were refolded through a multi-step dialyses against buffers in 
decreasing concentration of urea. Dialyses membranes with the appropriate cut off 
were kept under agitation at 4°C O.N. The steps were the following: 
 
• Urea 6 M, Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer 
• Urea 4 M, Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer 
• Urea 2 M, Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer 
• Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer 
 
4.4 Protein trans-splicing reaction  
 
4.4.1 CCS D1D2-IntN and CCS IntC-D3 constructs 
Protein trans-splicing reaction was performed following a reported protocol 
(Muona et al. 2010). CCS D1D2-IntN and CCS IntC-D3 purified proteins, 
suspended in Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer, were mixed 
equimolarly at a final concentration of 20-100 μM in a volume of 10-50 ml.  The 
reaction was carried out for 24 h at different temperatures (25°, 30° or 37°C) 
without shaking. During the ligation reaction, several withdrawals (10 μl each) were 
made at different time to check the reaction progression through SDS-PAGE gel. 
Every 10 μl aliquot was mixed with 1 x SDS sample buffer and stored at -20°C until 
the analysis.  
The protein trans-splicing reaction under denaturing conditions was performed 
following the previously reported protocol at 4M urea concentration.  
 
4.4.2 Strep-MBP-TEV-CCS_D1D1-IntN and MBP-IntC-CCS_D3_SGV 
Strep-MBP-TEV-CCS_D1D1-IntN and CCS IntC-D3 bacterial cell pellets were 
resuspended in Tris 20 mM, NaCl 0.5 M, TCEP 0.5 mM pH 8 buffer and mixed 
with 1:3 ratio in a total volume of ~60 ml. After some cycles of sonication, the 
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soluble fraction was separated from the cellular debris through centrifugation at 
8000 rpm for 90’. The mixture was then incubated at room temperature for 24h 
without agitation. Aliquots were taken at different time for monitoring the reaction.  
After 24 h the reaction mixture was loaded onto a previously equilibrated His-trap 
affinity Ni-column and washed with Tris 20 mM, NaCl 0.5 M, Imidazole 0.5 mM, 
TCEP 0.5 mM pH 8 buffer. The elution was performed using Tris 20 mM, NaCl 
0.5 M, Imidazole 0.5 M, TCEP 0.5 mM pH 8 buffer.  
A size-exclusion chromatography using a Superdex75 16/60 column washed with 
Tris 20 mM, NaCl 0.5 M TCEP 0.5 mM pH 8 buffer was run. Finally, an anionic 
exchange chromatography was performed. The protein was eluted in Tris 20 mM, 
TCEP 0.5 mM pH 8 buffer and loaded onto a Hi-Prep Q HP 16/10. Tris 20 mM, 
NaCl 0.5 M TCEP 0.5 mM pH 8 buffer was used for the elution step.  
 
4.5 Polyacrylamide gel electrophoresis  
 
SDS-PAGE methodology was used to separate and thus identify expressed proteins 
depending on their electrophoretic mobility through a polyacrylamide gel. Protein 
aliquots of 10 μl were mixed with 1 x sample buffer containing sodium dodecyl 
phosphate (SDS) and boiled for 5 minutes. After 1’ of centrifugation at 16000 x g, 
6 μl of each sample was loaded on polyacrylamide gradient 4-20% mini-
PROTEAN® TGX™ precast protein gel (BIORAD). Electrophoretic run was 
performed for at least 25’ at 200 V using 25 mM Tris, 192 mM glycine, 0.1% SDS 
buffer in a mini-PROTEAN® vertical electrophoresis chamber (BIORAD). Proteins 
were then stained using Coomassie brilliant blue dye (Giotto biotech).  
 
4.6 Western Blot analysis (WB) 
 
Western Blot technique was performed to identify the protein of interest, i.e. FL-
CCS through the use of highly specific antibody. Proteins previously separated by 
size thanks SDS-PAGE were transferred onto a nitrocellulose-matrix membrane 
(BIORAD) using a trans-Blot Turbo machine (BIORAD). The membrane was 
incubated for 1 h at room temperature in a 5% of non-fat dry milk Tris-buffered 
saline (TBS) solution with 0.005% of Tween-20 detergent to saturate all the non-
specific binding sites. The blocking phase was followed by a 2h of incubation at 
room temperature with a monoclonal primary anti-FL_CCS antibody. After a series 
of 10 minutes washes with TBS 1x, a secondary antibody conjugated with 
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peroxidase enzyme was used to incubate the membrane at least for 1h at room 
temperature. A last wash with TBS 1x was then performed. The protein-antibody 
complexes were detected thanks to a chemiluminescent reaction obtained through 
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